UBC Clinical Research Ethics General Guidance Notes

These Guidance Notes (GNs) provide the most up-to-date overview of the UBC clinical Research Ethics Boards' policies and guidance concerning clinical research ethics at UBC.

They are applicable to all UBC affiliated clinical Research Ethics Boards (REBs) [the Clinical Research Ethics Board (CREB), Providence Health Care REB, Children's and Women's REB, and BC Cancer REB. However, each board may have separate Application Guidance Notes (AGNs) that are based on each individual board's practices and should be read together with the overarching clinical Guidance Notes.

Please refer to the separate Post-Approval Activity Guidance Notes on the Office of Research Ethics website for information pertaining to:

  • Annual Renewals
  • Amendments
  • Requests for Acknowledgement
  • Completion of Studies
  • Protocol Deviations
  • Unanticipated Problems

Guidance Notes by Section

Part A1: The Roles and Responsibilities of the Researcher and the Research Ethics Board
Part A2: The Principles of Review
Part B: RISe Application Guidance Notes (AGNs)
Appendix: Acronyms and Glossary

If you wish to search for a specific term in the page, please first expand all of the content.     Open All  

AnchorPart A1: The Roles and Responsibilities of the Researcher and the Research Ethics Board


Guidance Note 1: Authority of the UBC-Affiliated REBs

The UBC REBs are established and empowered under the authority of the Board of Governors, through the Vice-President Research. They operate under the authority of UBC Policy #LR9 on "Research and Other Studies Involving Human Subjects". UBC administration, under the direction of the Vice-President Research, is ultimately responsible for overseeing the protection of human participants involved in research programs conducted by the University. University administration is responsible for ensuring that sufficient resources are allocated to the UBC Research Ethics Boards to allow them to perform their review, record-keeping and monitoring functions.

Purpose of the REBs: UBC's Research Ethics Boards are autonomous entities whose primary responsibility is to protect the rights and welfare of human participants taking part in research conducted under the auspices of UBC. The UBC REBs review and oversee such research to assure that it meets ethical principles and that it complies with all applicable regulations and standards pertaining to human participant protection. These include but are not limited to:

The Tri-Council Policy Statement TCPS 2 (2018): Ethical Conduct for Research Involving Humans

Health Canada's Food and Drugs Act

The International Conference on Harmonization Good Clinical Practice: Consolidated Guidelines

The Declaration of Helsinki

The U.S. Common Rule (for studies funded by the U.S. Government or regulated by the US Food and Drug Administration)

UBCs REBs have the authority to approve, require modifications in, or disapprove any research activity that falls within their jurisdiction.

UBC's REBs are required to conduct continuing ethical review of every approved study. Continuing review activities include, but are not limited to:

  • Review of regular progress reports including renewals
  • Review of changes in the design or conduct of the study prior to implementation
  • Review of serious adverse events and other unanticipated events, including protocol deviations
  • Monitoring to determine that the study is conducted as approved
  • Monitoring of the informed consent process
  • Suspension or termination of the approval of a study
  • Placing restrictions on a study
  • Any other review procedure deemed necessary to protect the rights and welfare of human participants.


Guidance Note 2: Jurisdiction of the UBC-Affiliated REBs

All research on human participants conducted at UBC facilities, (including UBC affiliated hospitals) or undertaken by individuals connected to the University must be reviewed and approved by a UBC sanctioned Research Ethics Board prior to it commencing. [See UBC Policy LR9, Article 7.8.1. Where such research is “conducted by members or associated members of the University acting in their University capacity".]

In some cases, a research project may need to be reviewed by more than one Board or Committee. For example, research that involves human blood may require review by both the Biosafety Committee and the Clinical REB.

Important Note: None of UBC's Affiliated REBs will review or acknowledge research that has already been conducted. Requests for such review to satisfy, for example, publication or graduation requirements, will not be entertained.

One Board of Record: The UBC Research Ethics Boards that review research involving human participants have signed a one board of record agreement allowing approvals by one UBC-affiliated REB to be recognized by the other UBC-affiliated REBs. Research conducted by the same researcher at multiple UBC sites needs ethical approval from one UBC-affiliated REB only. Most sites will, however, require separate approval for resource allocation purposes, e.g. hospitals. Although there is one REB of Record, in order to ensure that institutional specific ethics requirements are being met, the Chair and the Manager of each UBC REB for the institution(s) involved in the research have the ability to view the application approved by the REB of Record. If the REB Chair of any institution involved in the research has questions or concerns, these will be directed to the REB Chair of the REB of Record for resolution. The REB Chair of any institution involved as a research site may refer a question or concern to the REB of Record at any time. The UBC-affiliated REB that initially reviews a research study will normally be the REB of Record. All activity involving the study that occurs subsequent to the initial approval (such as amendments, annual renewals, requests for acknowledgement) should be submitted to the REB that is the REB Board of Record.

Six REBs: UBC currently has six Research Ethics Boards that review and approve research studies involving human participants that are conducted under the auspices of UBC. Each individual Board has varying operational practices, and researchers are advised to familiarize themselves with the processes of the Boards that they submit applications to. Each Board has its own web-site to assist researchers with information concerning submission deadlines, meeting dates etc.

The Behavioural REB reviews research on humans that is behavioural or social scientific in nature or involves humanities research and that may involve the study of patients or health care providers. Behavioural studies are not clinical in nature and ­do not involve any invasive procedures. These types of studies include research involving interviews, administration of questionnaires, tests and/or observations. They can include the use of medical records but with consent.

The Okanagan REB reviews research that would otherwise be reviewed by the Behavioural REBs, which is being conducted by individuals affiliated with UBC-Okanagan.

The BC Cancer REB, the Children's & Women's REB and the Providence Health Care REB review research being conducted at these sites. If a UBC-affiliated researcher wishes to conduct research at ONLY one of these sites, they must submit their application to that site. If a UBC Researcher wishes to conduct research at other non-UBC affiliated sites, but not at a UBC-affiliated site, he or she should submit their research to the REB where they hold their primary appointment. UBC researchers who wish to conduct research at MULTIPLE UBC-affiliated sites have the option of having their study reviewed by any UBC-affiliated REB. It is recommended that they utilize the Board associated with the institution where they hold their primary appointment.

The Clinical REB reviews research that involves clinical interventions such as surgery, the administration or testing of drugs, medical devices, medical imaging or diagnostic techniques, taking of blood or other specimens, exercise programs, the analysis of clinical -e.g. laboratory, physiological or biological - data obtained from medical records or studies of a clinical nature involving the linkage of data from existing databases, or any invasive procedure involving an element of risk. The CREB reviews research being conducted at the UBC Hospital (Point Grey) site, and the Vancouver Coastal Health Authority Sites.

At the discretion of the Chairs and Managers of the UBC REBs, a submission may be re-directed to a more appropriate REB.

Please consult with the administrative REB staff if you are not sure which REB you should apply to.  

For the review of harmonized applications please see Research Ethics BC.  Research Ethics BC supports a provincial, harmonized system for research ethics reviews of multi-jurisdictional studies involving human subjects (i.e. involving the resources, people, patients or data from more than one BC institution). It’s founded on a collaborative effort by a group of BC health research partners to develop the harmonized ethics review models now in use by most BC health authorities and research universities.


Guidance Note 3: Principal Investigator Responsibilities
Guidance Note 3.1: Principal Investigators

AnchorAll Principal Investigators must have a faculty appointment at UBC or if permitted by the applicable board, a staff appointment at an affiliated institution. Principal Investigators bear the overall responsibility for the conduct of the study, including the activities of co-investigators and others on the study team. As the individual responsible for the implementation of the research, the principal investigator bears direct responsibility for ensuring the protection of every research participant. All Principal Investigators are required to meet the responsibilities assigned to them in UBC Policy #LR9, Procedures. These responsibilities include, but are not limited to:

  • Bring to the attention of the Head of his/her department any research or other study proposed by him or her, or proposed by a student working under his or her direction, that could be defined as a study involving human participants.
  • Present sufficient information to the Head to enable a judgment to be made by him or her as to whether the project comes within the definition of research involving human participants.
  • Submit Research for REB review in the form and with the content specified in the UBC Human Ethics Application
  • Include as part of each REB application a process for continuing review appropriate to the project.
  • Promptly inform the REB that is considering, or will consider, an application by the researcher for any similar or equivalent proposal to:
    • other REBs;
    • funding agencies or regulatory bodies; or
    • research ethics boards, or the like, of other institutions.
  • Maintain any issued Certificate of Approval in good standing during the research project.
  • Promptly notify the REB that issued a Certificate of Approval of any change in the research involving human participants as proposed and when the project concludes.
  • Ensure that informed consent, when required, is obtained from research participants prior to their enrolment into the research project in a form and manner prescribed by TCPS2, UBC Ethical Directives and other relevant national and international standards or condition of funding, where applicable.
  • Report all serious and unexpected study related events to the applicable REB in accordance with applicable regulations and guidelines.
  • Ensure that any amendments to the study personnel, funding, protocol, consent form or any recruitment procedures are approved by the applicable REB prior to implementation, except where necessary to eliminate apparent immediate hazards to human participants.
  • Promptly notify the applicable REB of any unexpected incident, experience or outcome, or any new research knowledge that could impact the conduct of the study or alter the REB's approval or favourable opinion to continue the study.
Guidance Note 3.2: Investigators Conducting Clinical Trials

AnchorInvestigators conducting clinical trials for either drugs/radiopharmaceuticals, devices or natural health products used for therapeutic purposes have special obligations that are defined in the Food and Drugs Act Regulations that govern each type of experimental therapy. If the study is investigator-initiated, the Investigator bears additional regulatory responsibilities as a study Sponsor. Application Guidance Note #7.11 outlines REB requirements pertaining to regulatory approvals and registration of clinical trials. Investigators conducting clinical trials must also ensure that they comply with the provisions of the TCPS 2 (2018) and the International Conference on Clinical Trials Good Clinical Practice: Consolidated Guidelines.

Guidance Note 3.3: Investigators Conducting Research Funded or Supported by the United States Federal Government or Regulated by the U.S. Food and Drug Administration.

Anchor Investigators (and their institutions) that receive funding or support for studies from the U.S. Federal Government or its agencies are subject to the requirements of the Department of Health and Human Services, found at 45CFR46 (for a list of the applicable agencies click here).

Investigators (and their institutions) that conduct studies that are regulated by the U.S. Food and Drug Administration (including but not limited to most privately funded clinical trials) are subject to the requirements of the U.S. Food and Drug Administration, most of which are found at 21CFR50 and 21CFR56.

Investigators conducting studies that are subject to the U.S. regulations are responsible for ensuring that they comply with these additional requirements, and in particular, the requirements for reporting unanticipated problems to the Research Ethics Board and if necessary to the applicable regulatory agency. Click here to link to the DHHS Regulations, 45CFR46. Click here to link to the U.S. Food & Drug Administration Regulations, 21CFR50 and 21CRF56.


Guidance Note 4: Types of Research that Require Review
Guidance Note 4.1: Scope of REB Review Requirements

AnchorAll research involving human participants and all other activities that even in part involve such research, regardless of sponsorship, must be reviewed and approved by a UBC-affiliated REB. No intervention or interaction with human participants in research, including the use of their data, tissue, or the initiation of recruitment, may begin until a UBC REB has reviewed and approved the research protocol, consent documents, and recruitment materials and has issued a certificate of approval. Specific determinations as to the definition of "research" or "human participants", and their implications for the jurisdiction of the REB under University of British Columbia policy are determined by the REBs. Determination of exemption from REB review must be based on regulatory and institutional criteria.

Guidance Note  4.2: Definition of Research and activities that require REB Review

AnchorResearch involving human participants is defined as an undertaking intended to extend knowledge through a disciplined inquiry or systematic investigation that includes the following:

  1. Living human participants; and/or
  2. Human biological materials, as well as human embryos, fetuses, fetal tissue, reproductive materials and stem cells. This applies to materials derived from living and deceased individuals. TCPS 2 (2018), Article 2.1

Human Participants are those individuals whose data, or responses to the interventions, stimuli or questions by the researcher, are relevant to answering the research question.

Human biological material include tissues, organs, blood, plasma, serum, DNA, RNA, proteins, cells, skin, hair, nail clippings, urine, saliva and other body fluids.

The following are examples of types of research involving human participants:

  • administering a drug, taking a blood sample, doing a test or performing a procedure, clinical, therapeutic or otherwise, upon a person, for research rather than treatment;
  • asking people for information whether by telephone, letter, e-mail, internet, survey, questionnaire or face to face interview;
  • using non-public records that contain identifying information previously gathered about anyone, either directly or indirectly;
  • using identifiable information previously gathered about anyone, (e.g., secondary data analysis. See definition of "identifiable");
  • observing anyone's responses or behaviour, either directly or indirectly.

All research involving living human participants (faculty, patients, staff, students or members of the community), all research involving tissues, fluids, biological fluids, embryos or fetuses, or cadaveric remains, all research in which access to human participants involves any records maintained by UBC or any of its affiliated Hospitals, and all research involving data collected from human participants which is to be carried out by faculty, staff or students of the University of British Columbia, shall be reviewed and approved in advance by the REB.

Please note that if your study is funded or supported by the U.S. Federal Government or subject to U.S. Food & Drug Administration oversight and regulations, somewhat different definitions apply. Research funded or supported by the U.S. government is any activity that either: 1) meets the HHS definition of "research" and involves "human participants" as defined by the HHS regulations 45CFR46 102(d)(f) or 2) meets the FDA definition of "clinical investigation" and involves "human participants" as defined by the FDA regulation 21CFR50.3(c)(g).

Guidance Note 4.3: Research Exempt from REB Review

AnchorResearch situations that are exempt from the REB review include the following. Note that the opinion of the appropriate REB should be sought if there is any doubt about the applicability of any of the below criteria.

4.3.1: REB review is not required for research that relies exclusively on publicly available information that is legally accessible to the public and appropriately protected by law or is publicly accessible and there is no reasonable expectation of privacy. 

See the TCPS2 (2018) Article 2.2 for examples of and additional information pertaining to the concepts of publicly available information, legally accessible information, and reasonable expectation of privacy.

4.3.2: REB review is not required for research involving the observation of people in public places where there is no intervention or interaction on the part of the researcher, the targeted individuals or groups have no reasonable expectation of privacy, and the dissemination of research results would not allow for the identification of individuals. TCPS 2 (2018), Article 2.3

4.3.3: REB review is not required for research that relies exclusively on secondary use of anonymous information or anonymous human biological materials, provided that the results do not generate identifiable information. Refer to  CREB Guidance Notes for Research Involving Human Biological Materials.

Secondary use refers to the use in research of information originally collected for a purpose other than the current research purpose. TCPS 2 (2018), Article 2.4 When this information was collected anonymously, it can be used for research purposes without REB review. (See Guidance Note #5 for a discussion on secondary use of data and biological information where REB review is required). Examples of anonymous secondary use data may include datasets from a QA/QI survey or questionnaire where the participant's identity was never known.

Important Note: In accordance with Article 7 of UBC Policy #LR9 , genetic material shall not be considered anonymous unless a REB determines otherwise.

Guidance Note 4.4: Activities Not Requiring REB Review
Guidance Note 4.4.1 Quality Assurance and Quality Improvement:

AnchorAnchorQuality assurance and quality improvement (QA/QI) studies, program evaluation activities, and performance reviews, or testing within normal educational requirements, when used exclusively for assessment, management or improvement purposes, do not constitute research under the TCPS 2 (2018)and do not fall under the scope of REB review. TCPS 2 (2018), Article 2.5 However, QA/QI projects that contain an element of research do require review and a determination of whether a project requires review is often difficult to make. Researchers who are unclear as to whether a project is solely QA/QI should complete the jointly created VCHRI-UBC tool designed to assist researchers to decide whether or not their project constitutes research requiring review or whether it is quality assurance and does not. Click here to access the tool. If after completion of the QA/QI tool you are still unsure as to whether or not your project constitutes research, please consult with the applicable REB administration.

An intention to publish QA/QI results does not necessarily mean that the project needs REB review. If an academic journal requires REB oversight or review for publication, consult with the appropriate UBC REB prior to commencing the project. Each REB has different administrative processes in this regard. Note that many journals do not directly ask for REB approval but rather whether the activity meets the ethical requirements of the country. In these cases, if the project was truly QA/QI then an appropriate answer would be the following: Yes, under article TCPS 2 (2018), Article 2.5, the overarching ethical framework for research involving human participants in Canada, QA/QI activities are exempt from Research Ethics Board review.

*Please note that if your project will be accessing VCH patient records, please contact UBC CREB to determine if your project qualifies as QA/QI.

Guidance Note 4.4.2 Case Reports


Individual case reports may not meet the definition of research, depending upon the intent of the report.  Individual (single) or at most, two case reports may be considered a medical / educational activity, with no research intent, provided that they are not intended to be generalizable beyond the one or two incidents.    Please contact your REB for a consultation and discussion if you are planning to conduct a case report.  UBC REBs expect that patients will be made aware that the author / investigator plans to create a report about their case which may be published.  Ideally a written consent to publish will be obtained.  Case reports for REB purposes are a retrospective analysis of one or two clinical cases. If more than two cases are involved in the analytical activity, the activity will normally constitute "research" and be subject to ethics review.

This does not imply that there are no ethical issues, as there are confidentiality and privacy matters that need to be addressed.   There should be a process in place to ensure that the patient is aware that you plan to publish a report about their case. It would be prudent to obtain consent from the individual.  This may also be verbal and documented in the medical records.


Guidance Note 5: Proportionate Review and Minimal Risk Studies
Guidance Note 5.1: The Principle of Proportionate Review

AnchorUUBC REBs use a proportionate approach to review research involving human participants. They review applications in accordance with the level of risk that the proposed study poses to the research participants: the lower the level of risk, the lower the level of scrutiny; the higher the level of risk, the higher the level of scrutiny. In accordance with the TCPS 2 (2018), full review by a fully convened REB is the default requirement, unless the REB has determined that the research is of minimal risk and that delegated review by one or more experienced reviewers appointed by the REB is appropriate. UBC REBs have different procedures for delegated review, in accordance with individual Board policies. UBC REBs retain the right to decide to put any application submitted for minimal risk review forward for full board review.

UBC also strives to use a proportionate approach for multi-jurisdictional studies, i.e. research studies that require review and approval by more than one Canadian research ethics board as a result of the requirements of the TCPS 2 (2018), Article 2.1 or due to UBC's institutional policies. UBC is implementing a variety of processes and entering into agreements with other Canadian Institutions in an effort to avoid duplicate ethical reviews of research; in particular, duplication of review by a fully convened UBC REB in circumstances where a research study has previously been reviewed by a fully convened REB at another Canadian institution.

Guidance Note 5.2: Definition of Minimal Risk

AnchorMinimal risk is defined in the TCPS 2 (2018) as follows: if potential participants can reasonably be expected to regard the probability and magnitude of possible harms implied by participation in the research to be no greater than those encountered by the participants in those aspects of their everyday life that relate to the research. UBC currently recognizes the following categories of clinical research as meeting the criteria for minimal risk and being eligible for delegated review.

Note: If a study is funded or supported by the US Federal government or is subject to the US Food and Drug Administration regulations, only studies that meet the U.S. definition of minimal risk and that are listed in the U.S. Federal Register may be considered as qualifying for delegated / expedited review.

Guidance Note 5.3: Types of Minimal Risk Research Studies that may qualify for Delegated Review
Guidance Note 5.3.1 Studies relying exclusively on secondary use of data e.g. previously collected / existing clinical data, medical records, or other personal records


  1. Studies using existing database / registries or linking information between databases 
  2. Studies using previously collected data from existing documents, records or charts (generally "retrospective chart reviews"). Case reports involving 1 or 2 clinical cases do not require REB review (refer to Article 4.2), however, reviewing more than 2 cases is considered research and requires REB review.
  3. Studies using previously collected clinical specimens where there is no current or future clinical need for the specimens
Guidance Notes 5.3.2 Studies intending to collect and analyze specific types of data


  1. Studies that will involve only the collection of hair, nail clippings, deciduous teeth, excreta, salivary secretions, additional swabs or other external secretions that have been collected in a non-invasive manner and that may also be collected as part of routine clinical care.
  2. Studies that involve only the collection of placenta or amniotic fluid as a consequence of childbirth, or fetal tissue collected as a consequence of therapeutic abortion or miscarriage.
  3. Studies that involve only the collection of blood samples either (a) by venipuncture, or (b) by a central line where that central line is both already present as part of clinical care, and was installed as part of clinical care.
  4. Studies that involve clinical data collected prospectively as part of clinical care.
Guidance Notes 5.3.3 Studies that involve only questionnaires or surveys


Studies that involve only questionnaires or surveys should generally be sent to the Behavioural Research Ethics Board, unless they are clinical in nature. If the questionnaires involve sensitive information from vulnerable populations or significant nuisance or inconvenience they will generally not qualify for delegated review.  Please see the following BREB Guidance on Using On Using Online Surveys

Guidance Note 5.3.4 Exercise Studies


  1. Studies that will involve the collection of output data obtained as a result of moderate exercise undertaken by healthy volunteers
  2. Studies that will involve the collection of output data obtained as a result of maximal exercise by healthy volunteers who are less than 40 years old. In these cases, the REB must receive and approve a safety protocol.

Note: Exercise in a patient population will generally be referred to the full board unless the exercise being observed is part of standard care.

Guidance Note 5.3.5 Scans


Studies using data recorded using non-invasive procedures such as EEG, EKG, MRI, ultrasound or x-rays will generally meet the criteria for minimal risk.

Note: X-rays will not be expedited if the radiation exposure is in excess of 0.01 mSv (the approximately equivalent of one return transcontinental airline flight). For additional guidance on X-ray exposure and PET scans, please refer to Guidance Note # 17.

Guidance Notes 5.3.6 Stem Cell Research


  1. Stem cell research qualifies for delegated review with the exception of any research that concerns the derivation of stem cell lines from human somatic tissue, umbilical cord or placenta OR research involving the grafting of stem cell lines into humans.
  2. Research that uses permanent stable cell lines in laboratory research (i.e. in vitro) does not require ethical review.
Guidance Note 5.3.7 Observational research on Standard Treatment(s)

AnchorObservational research on standard treatment(s) where the treatment(s) is (are) determined clinically and not assigned by research methodology (e.g. randomization).

Guidance Note 5.4: Types of Minimal Risk Studies That Require Full Board Review

AnchorThe following types of studies may require full board review depending upon board specific policy.

  1. Studies whose purpose it is to collect or use tissue/DNA for the purpose of creating a tissue/DNA bank or adding new sources of tissue to a tissue/DNA bank.
  2. Studies whose purpose it is to collect or use tissue/DNA for genetic research related to determining susceptibility of acquiring a disease; or studies whose purpose it is to collect or use tissue/DNA for genetic research the results of which could be potentially harmful to participants if disclosed.
  3. Studies whose purpose is the derivation of stem cell lines from human somatic tissue, umbilical cord or placenta OR research involving the grafting of stem cell lines into humans.
  4. Minimal risk studies where a waiver of consent or alteration of the required elements of informed consent is being requested.
  5. Minimal risk studies that will be recruiting vulnerable populations and there may be increased risk.

The following types of studies do not require full board review when a waiver of consent or an alteration of the required elements of informed consent is being requested.

  1. Retrospective chart reviews,
  2. studies using data obtained from previously banked anonymized tissue that is not linked to other sources of data,
  3. Studies using data from provincially regulated databases/registries (e.g Medical Services Plan, BC Centre for Disease Control) or from disease specific registries with data collected from participants who have already consented to its use for the sort of research being done.
  4. Prospective chart or medical record reviews where the data has been de-identified through an acceptable privacy guardian program or anonymized (i.e., there is no way to link the data to the participant), and there is no potential harm to the participant.
  5. Prospective chart or medical record reviews where members of the research team are not in contact with participants during the data collection and where the researcher has provided an appropriate justification for why contacting the participants to obtain consent would be impracticable.

Important Note: For guidance pertaining to informed consent requirements for Minimal Risk studies please see Guidance Notes 13 and 14.



Guidance Note 6: Governing Principles and Criteria for Review and Approval
Guidance Note 6.1: Governing Principles

AnchorUBC REBs are guided by the ethical principles regarding all research involving human participants as set forth in the Tri-Council Policy Statement 2 (2018): Ethical Conduct for Research Involving Humans. The TCPS 2 (2018) core principles are based in the underlying value of respect for human dignity and are as follows:

For a thorough discussion of the TCPS2's core principles, see Chapter 1 of the TCPS2.

Guidance Note Article 6.2: Minimal criteria for approval of research

AnchorIn order for a research project to be approved, the REB must find that:

  1. The Investigator (and his/her team) has the credentials to conduct the research.
  2. There are no conflicts of interest which will compromise the safety or well-being of participants.
  3. The research will generate knowledge that could lead to improvements in health or welfare.
  4. The methodology must be scientifically sound and capable of answering the research question.
  5. Risks to participants are minimized:
    1. By using procedures which are consistent with sound research design and which do not unnecessarily expose participants to risk, and
    2. Whenever appropriate, by using procedures already being performed on the participants for diagnostic or treatment purposes.
  6. Risks to participants are reasonable in relation to anticipated benefits, if any, and the importance of the knowledge that may be expected to result. In evaluating risks and benefits, the REB will consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies those participants would receive even if not participating in the research).
  7. Selection of participants is equitable. In making this assessment, the REB will take into account the purposes of the research and the setting in which the research will be conducted and will be particularly cognizant of the special problems of research involving vulnerable circumstances, which have historically included children, elderly, prisoners, pregnant women, those with mental health issues, and those with diminished capacity for self-determination. 
  8. Recruitment methods which respect the privacy of individual participants must be followed. Except under unusual circumstances, only members of the participant's/patient's healthcare team may approach the participant/patient regarding participation in the study.
  9. Informed consent will be sought from each prospective participant or the participant's legally authorized representative, in accordance with and to the extent required by appropriate local, provincial or national guidelines or regulations.
  10. Informed consent will be appropriately documented as required by local, provincial and federal regulations.
  11. Any waiver or alteration of the informed process will be properly justified and documented.
  12. Where appropriate, the research plan makes adequate provision for on-going monitoring of the data collected to ensure the safety of participants.
  13. Where appropriate, there is adequate provision to protect the privacy of participants and to maintain the confidentiality of data.
  14. When some or all of the participants, such as children, prisoners, elderly, pregnant women, those with mental health issues, and those with diminished capacity for self-determination, are likely to be vulnerable to coercion or undue influence or international sites are used, additional safeguards have been included in the study, and in the REB review process to protect the rights and welfare of these participants.
  15. The resources required for successful completion of the study are committed (e.g., funding, space, personnel, etc.).
Guidance Note 6.3: Other Requirements
Guidance Note 6.3.1: Other Criteria


UBC REBs may require verification of information submitted by an investigator. The need to verify any information will be determined by the REB at a convened meeting. The purpose of the verification will be to provide necessary protection to participants when deemed appropriate by the REB.

Guidance Note 6.3.2: Cooperative Research Arrangements

AnchorThe VPRI may enter into joint review arrangements, rely upon the review of another qualified REB, or make similar arrangements to avoid duplication of effort as allowed.  Where necessary, the Institutional FWA will be appropriately modified, and REB Authorization Agreements will be entered into.

Guidance Note 6.3.3 US Federally Funded Research

AnchorFor research that is subject to the provisions of 45CFR 46 or 21CFR56, the researcher should ensure that they include the listed criteria in the applicable regulations, to the extent that they differ from or vary the criteria noted in 6.1 and 6.2 above


Guidance Note 7: REB Decisions and Term Approval
Guidance Note 7.1: REB Determinations

AnchorThe REB may make one of the four following determinations as a result of its review of research submitted for initial or continuing review: Approval, Proviso, Deferral, or Disapproval.

Approval (approve the application as submitted, including the consent form):

  • When an acceptable risk/benefit ratio exists and the regulatory criteria required for approval are satisfied (including Institutional approvals) and the approval to proceed is not withdrawn by the Vice‐President Research, the Board of Governors, or the President, the research may be approved as submitted,
  • For studies reviewed by the Full Board, the approval date is defined according to the date of the Full Board REB meeting review,
  • For studies reviewed via delegated review, the approval date is defined according to the date the reviewer confirms approval via RISe and the Certificate of Approval is released,
  • Studies will expire within one (1) year of the date in which the study was approved.

Provisos (approval with modifications/clarifications):

  • When an acceptable risk/benefit ratio exists, and the regulatory criteria required for approval are satisfied, but the REB members require modification to any aspect of the application or clarification or further information to secure approval, the REB may recommend “Provisos”,
  • A written explanation of the conditions and/or modifications is sent to the Researcher by the Chair of the REB through the REB Office Personnel, via the RISe system,
  • When the REB recommends “Provisos”, the REB Chair or designee should ensure that the additional information, modifications, or clarifications required are identified at the REB meeting and that the procedures for reviewing the additional information and issuing the approval are clear. The responsibilities for additional review and the decision regarding approval conditions should be delegated to one of the following:
    • The REB Chair alone,
    • The REB Chair and one or more named REB members that were present at the REB meeting or who submitted written comments on the application,
    • A sub‐group of the REB members designated by the REB Chair or designee or by the REB,
    • A designated REB member or members with sufficient knowledge and experience regarding the research and the regulations,
    • Qualified REB Office Personnel following the UBC‐affiliated REB’s
    • Approval Decisions – Delegation to REBA SOP;
  • In deciding the procedures to be followed, the REB should consider the significance of the requested additional information or modifications and the expertise necessary to assess it. Where the information or
  • modifications are straightforward, it is acceptable to delegate the consideration of that material to the REB Chair or designee alone,
  • Where the additional information/modification is technical (e.g., statistical clarifications), the REB Chair or designee should review the information with consideration given to involving other REB members, such as the lead reviewer(s) or relevant expert member(s),
  • When the Investigator provides the Research Ethics Board with proof that the conditions have been met and the documents have been amended, (as confirmed by the REB Chair or designee), the Certificate of Approval will be sent to the Researcher,
  • If the Researcher’s response is incomplete and does not fully address the matters raised, requests for further information, modifications or clarification should be sent to the Researcher,
  • The reviewers may decide upon reviewing the Researcher’s response that the decision should be deferred and that the application and the Researcher’s response materials should be reviewed at a subsequent Full Board meeting (see ‘Deferral’ process below),
  • The approval date is defined according to procedures listed under “Approval” above. The expiry date of the REB approval is calculated from this date; however, the Certificate of Approval is not issued until all of the conditions for approval have been met.​​​​​​

Deferral (defer decision‐making on the application and continue the deliberation of the application at a future Full Board meeting):

  • The REB may defer a decision on any submitted research application if it does not have sufficient information to arrive at a determination, or if the REB requires extensive revisions to any part of the research,
  • The REB will defer its decision to a subsequent Full Board meeting when significant questions are raised during its review of the research and/or when the criteria required for approval have not been met,
  • The REB Chair or designee should ensure that all additional information, modifications or clarifications that are required are specifically identified at the Full Board meeting,
  • The research and the Researcher’s response materials shall be reviewed at a Full Board meeting,
  • Upon consideration of the research along with the response from the Researcher, at the Full Board meeting, the REB should issue its final decision (approved, provisos, deferral or disapproval),
  • Researcher responses must be received and reviewed at a Full Board meeting. The approval date is defined according to procedures listed under “Approval” above. The expiry date of the REB approval is calculated from this date; however, the Certificate of Approval is not issued until all of the conditions for approval have been met.


  • The REB may disapprove the research when it fails to meet the ethical standards for approval and where revision is unlikely to enable the REB to reach a positive determination,
  • No other UBC REB or Institutional Official may approve a study which has been previously rejected by a UBC REB. 
  • Disapproval cannot be decided through the delegated review mechanism. If the recommendation under delegated review is to disapprove the research, a final decision must be made by the REB at a Full Board meeting.
  • The REB Chair or designee should ensure that the reasons for the disapproval are identified at the Full Board meeting for communication to the Researcher. 
  • If the research is disapproved, the reasons for disapproval will be communicated to the Researcher and the Researcher will be given an opportunity to respond in person or in writing.  
  • A researcher may request reconsideration of a decision made by the REB and has the right to appeal the REB’s decision pursuant to the provisions of UBC Policy LR9, as well as SOP 409 “Reconsideration of REB Decisions and Appeal Process”.


Article 7.2: Term of REB Approval

AnchorIn accordance with the TCPS 2 (2018), UBC Policy LR9 and the US Federal Regulations, all research studies must be reviewed by the REB at least annually, if not more frequently. UBC REBs will not issue certificates of approval for terms longer than one year. The determination of what constitutes a one year term varies slightly, depending upon whether or not the study was reviewed by the full board process, by a delegated review process or whether or not it is a renewal of a previously approved study. Full Board Approvals are effective one year from the meeting date at which the application was reviewed and approved. Delegated review approvals are effective one year from the date that the delegated reviewer issued his or her approval of the study and the certificate was issued. Annual renewal approvals will be effective one year from the date of issuing of the certificate of approval, unless the annual renewal was required to be reviewed by the Full Board. If the annual renewal is required to be reviewed and approved in a full board meeting, the one year period will be effective from the date of the meeting in which the renewal application was reviewed and approved.

Please note that approval of study amendments does not affect the expiry date of the original certificate of approval or annual renewal.

UBC's REBs may issue certificates of approval for terms of less than one year. The Board's determinations will be based upon the design of the study in question, and the perceived level of risk to participants.


Guidance Note 8: Required Information
Guidance Note 8.1: Requirement for a Research Protocol or Proposal

AnchorAll of UBC's REBs mandate that a research protocol MUST be submitted for all research applications regardless of the type of study. These must be submitted as separate documents attached to box 9.1 of the RISe application form. Research proposals submitted to granting agencies may be used to meet this requirement. Protocols must include the following components:

  1. A background literature review (with accompanying references) that includes an explanation of the need/justification for the study.
  2. The study purpose
  3. Hypotheses
  4. Objectives
  5. Specification of endpoints/outcomes (if applicable)
  6. Research design including statistical analysis plan (if applicable) and
  7. Detailed research procedures

Important Note: The requirement for a research protocol is a UBC-wide REB policy. Your application will be sent back, and approval delayed, if a protocol is not submitted with your application. Ensure that ethical issues as implicated by the research design are addressed within in the protocol.

Guidance Note 8.2: Peer Review

AnchorFor all research, UBCs REBs must be satisfied that the value and the scientific validity of the study warrant it being conducted such that study participant's time and effort regardless of level of risk of the study, is not being expended with no corresponding benefit to either society or to the participants.

Minimal Risk Research: Clinical Research that poses no more than minimal risk may not require peer review. The REB must be satisfied about both the value and scientific validity of the study. Research in the humanities and social sciences that poses no more than minimal risk does not normally require peer review. TCPS 2 (2018), Article 2.7

More-than-minimal-risk research:

Peer review is required for all studies above minimal risk.  Peer review (sometimes referred to as scholarly or scientific review) is generally understood by UBC REBs as a review of the importance of the research question (value) and the validity of the methodology. Practices around scholarly review vary between disciplines, fields of research and groups. The primary goal of this requirement is to ensure that above minimal risk research protocols that are submitted for ethical review satisfy the relevant disciplinary standards in terms of both value and scientific validity. It is anticipated that this in turn will facilitate the ethics review process for the REB, reduce the number of provisos and deferrals issued to researchers, and improve the overall success of the research. 

Peer - Scientific Review Template March 17, 2017  must be completed and attached to an application when a protocol:

  1. Is above minimal risk; AND
  2. Has not undergone internal or external peer review (includes granting agency approval); AND
  3. Will be submitted to the UBC CREB.

Note that if your research proposal has received a scientific peer review form from an independent authority in your field of expertise, or from your trainee's supervisory committee, this should be attached to Box 9.8 of the RISe application form.  In these instances, you are not required to also have the CREB Scientific / Peer Review Form document completed.

Independent peer review: Scholarly review by an independent group of experts who are not affiliated with the institutional department conducting the research, or with the company sponsoring the clinical drug/device trial is preferable to peer review by experts who are not independent.

UBC's REBs Requirements: All more than minimal risk studies submitted to UBC REBs require a peer review or scholarly review, or an accepted argument about why one has not been obtained. Your application will be sent back to you, if you do not provide appropriate peer review information on page 4 of the RISe application. If you make an argument that one is not necessary and the REB does not agree, you may be asked to submit one as a condition of study approval.

Guidance Note 8.3: Other Required Information

AnchorDepending upon the nature of the study, the REB will require additional documentation to be submitted with the application for its review. Required documentation includes:

  • A draft informed consent form (unless waiver of consent is being requested)
  • Where applicable, assent forms, tissue consent forms, letters of initial contact recruitment letters or brochures or flyers, telephone scripts, radio or TV ad scripts, and advertisements
  • Where applicable all study materials including, questionnaires, interview scripts, patient diaries, patient wallet cards, tests or patient information or instruction pamphlets
  • Where applicable, the Investigator's Brochure, proof of appropriate agency authority or regulatory approval such as Health Canada no objection letters, school board approvals, agreements or contracts with aboriginal communities, etc.

(See Application Guidance Notes on Required Regulatory Approvals # 7.8.A and Registration of Clinical Trials Guidance Note # 7.11 )

Note that all additional documentation should be attached as separate documents, (e.g. not in the appendix of the protocol), to the appropriate box on page 9 of the RISe application. The certificate of approval populates from the boxes on page 9 of the application and failure to do this will result in a document not being listed on the certificate of approval (COA).  Box 9.9 does not populate on the COA and theses document are for reference only.

Wallet Cards
The CREB recommends that all participants enrolled in a clinical trial involving drug administration in which they are not continually in a controlled environment (hospital, research clinic, etc.) should be provided with a wallet card describing the basic information about the trial.

An example of such a card could be as follows:
Name of Participant
Name of Study
Participant Study Number (if applicable)
Name of Principal Investigator
Treatment they are receiving (or which they could be receiving if they are in a blinded study)
Contact information of investigator/research staff (not necessarily 24/7)


AnchorPart A2: The Principles of Review

Guidance Note 9: Inclusion and Exclusion Criteria
Guidance Note9.1: Requirement for Equitable Selection of Participants

AnchorIn accordance with the provisions of the TCPS2's principle of justice, the selection of participants must be equitable. In assessing this aspect of the research proposal, the REB will take into account the purposes of the research and the setting in which the research will be conducted and will be particularly cognizant of the special problems of research involving vulnerable circumstances. Vulnerability is often caused by limited capacity, or limited access to social goods, rights, opportunities and power. Individuals or groups in vulnerable circumstances have historically included children, women, prisoners, those with mental health issues and those with diminished capacity for self-determination. Special consideration will be given to the potential for inclusion of participants in vulnerable circumstances. The research proposal must never intentionally or inadvertently increase or exploit this vulnerability, nor should these types of populations be excluded from research, which is potentially beneficial to them as individuals or to the group that they represent.

Guidance Note 9.2: Participants who lack capacity to consent

AnchorIndividuals who lack capacity to consent to participate in research shall not be inappropriately excluded from research. However, the inclusion of participants who lack the capacity of consent must meet the requirements of the TCPS2, Article 4.6, which outlines the following criteria:

  • the research can be addressed only with participants within the identified group; and
  • the research does not expose the participants to more than minimal risk without the prospect of direct benefit for them; or
  • where the research entails only minimal risk, it should at least have the prospect of providing benefits to the participants or to a group that is the focus of the research and to which the participants belong.

Important Note: U.S. Federal Regulations differ in their approach to allowing individuals who are legally incompetent to consent to participate in research that is more than minimal risk and not of direct benefit to them. UBC's REBs are governed by the TCPS2 and will not approve such research unless the TCPS2 criteria are met.

Guidance Note 9.3: Exclusion Criteria

AnchorResearchers must not exclude individuals from participation in research on the basis of attributes such as culture, language, religion, race, disability, sexual orientation, ethnicity, gender, reproductive capacity, or age unless there is a valid reason for the exclusion, which is explained to the REB in the application. Individuals who are not proficient in the language used by UBC Researchers should not be automatically excluded from the opportunity to participate in the research. Researchers should consider appropriate measures to allow such individuals to participate.

See TCPS2, Chapter 4, Fairness and Equity in Research Participation, for further information on inclusion and exclusion criteria in research.

See Application Guidance Note #5.4 for tips on filling in your application appropriately

Guidance Note 9.3.1: Eligibility of HIV Sero-Positive Individuals in Clinical Trials

AnchorPolicy Statement: Research Involving HIV Sero-Positive Individuals in Clinical Trials:

1) The default position should be that known HIV sero-positive individuals should be included in clinical trials unless there is strong justification to exclude them. (Reference: NCIC CTEP Guidelines regarding the inclusion of cancer survivors and HIV-positive individuals in clinical trials are available at http://ctep.cancer.gov/protocolDevelopment/policies_hiv.htm

2) Any justification for exclusion must provide a compelling and detailed rationale based on the specifics of the study objectives, the nature of the experimental interventions being considered, the scientific rationale from a methodological perspective, and the relation of these to HIV status and/or the specifics of the individual drugs contained in HAART or other management. In early Phase I and Phase II clinical trials where the performance or maximum tolerated dose is unknown it may be reasonable to exclude this population or other similar high risk individuals until there is sufficient accumulative data.

3) For known HIV sero-positive individuals who are enrolled in clinical trials, it is suggested that a physician familiar with HIV care be involved or consulted.

4) Where HIV status is raised as an exclusion criterion, the justification should be provided within both the protocol and the consent form.

Background and Rationale:

Many clinical trials continue to list HIV sero-positive status as an exclusion criterion, often citing ‘safety concerns’ without further rationale.With the advent of modern HAART (highly active antiretroviral therapy) the clinical course of HIV-sero positive disease has changed dramatically, prompting a re-examination of the assumptions related to risks, safety and longevity for affected individuals. Furthermore, HIV sero-positive individuals are at the same or increased risk of the conditions for which clinical trials are often designed, and there is a need to know how best to manage such individuals.

In the pre-HAART era, concerns about enhancing risks related to immunosuppression and opportunistic disease associated with experimental treatments were legitimately used as a blanket exclusion of HIV sero-positive individuals from many clinical trials. Three other factors also contributed to their exclusion: 1) the prognosis of such individuals from their HIV status meant that including them in clinical trials could confound analyses, especially where survival was the primary endpoint; 2) their limited prognosis meant that HIV status as a competing risk lowered the prevalence of other conditions normally associated with advancing age (e.g., common cancers); and 3) concerns about the safety of laboratory personnel in handling HIV positive human biological materials.

In the HAART era, none of these factors currently justifies routine exclusion of HIV sero-positive individuals from enrolling in clinical trials. First, effective HAART therapy restores immune status and there is no evidence that exposure to most investigational therapies, including anti-cancer drugs, enhances risks of opportunistic infection. Furthermore, we now have the expertise to anticipate and manage such conditions.

Second, the life expectancy of HIV sero-positive individuals is approaching that of the general population so that their inclusion in clinical trials should not serve as a confounder in analyses. Furthermore, with the increased life expectancy, the prevalence of other chronic diseases is increasing. Thus, excluding HIV sero-positive individuals from clinical trials is discriminatory on the grounds that best management of these individuals in relation to the chronic diseases they acquire is not being studied.

Third, with the implementation of universal precautions in both clinical and research laboratories handling human biological materials, risks to health care workers and laboratory personnel are no longer an issue. Furthermore, it is estimated that there is a significant population for which HIV status is unknown, thus prompting the implementation of universal precautions.

The arguments against routine exclusion of HIV sero-positive individuals from cancer clinical trials are reviewed in the following citation: Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. Journal of Clinical Oncology 2008; 26: 10-27-32.

From the scientific perspective, it would be useful to stratify subjects according to HIV status if this is appropriate in order to learn more about any differences in performance of experimental agents and their risks in this population, and to be able to adjust analyses to account for these.

Application Statement

For example, exclusion on the basis of immune status would not be sufficient justification unless the exclusion criterion applied to all other conditions where immune status was a concern. Similarly, justification of exclusion based on drug interactions with HAART associated agents would not be appropriate unless there was evidence of the risk, and unless such a justification was applied to other drug interaction issues in HIV sero-negative individuals. Furthermore, “some patients can safely have their ART suspended during anti-neoplastic therapy to avoid potential deleterious pharmacokinetic and toxicity interaction.”(Little RF, Pittaluga S, Grant N et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101: 4653-9)

Guidance Note 10: Recruitment A
Guidance Note 10.1: Recruitment

AnchorAs stated in TCPS 2 (2018), Article 3.1 "the approach to recruitment is an important element in assuring voluntariness. In particular, how, when and where participants are approached, and who recruits them are important elements in assuring (or undermining) voluntariness."  It is the researchers' responsibility to demonstrate to the REB that their research methodology adheres to the principle of voluntariness.

Guidance Note 10.1.1: Information Required by the REB

AnchorThe UBC REBs require information concerning how potential study participants are identified and initially contacted. In particular, this information should include a description of the following:

  1. The source (i.e. its original purpose, if relevant) of the contact information, and how the researcher gained access to it;
  2. Who will collect the contact information;
  3. Who will make the initial contact with the prospective participant(s);
  4. How the prospective participant will be initially contacted;
  5. When the prospective participant will be initially contacted;
  6. The relationship, if any, of the study team members to the participants (e.g. treating physician, teacher); and
  7. All recruitment materials such as letters, advertisements, flyers, television or radio scripts, internet/e-mail messages
Guidance Note 10.1.2: Ensuring Recruitment is Free from Undue Influence

AnchorThe REB prefers that initial contact of prospective participants be by someone who is within their circle of clinical care (this is not a defined term, but for assistance in assessing its meaning, researchers may review a document prepared by the Ontario Privacy Commissioner called "Circle of Care: Sharing of Information for Health Care Purposes". However, UBC's REBs also recommend that a treating physician/care provider, who is also an Investigator in a study, not be the person making the initial contact with the potential participants unless this is necessary due to the requirements of the study design or because of limited resources. It is preferable to have initial contact by someone who is not in a relationship of power and/or authority over the potential participants, due to the potential for undue influence (e.g. when the investigator is also providing medical care to a prospective participant or when there is a relationship of investigator-teacher and participant-student).

Whenever possible, when inviting potential participants a method free of the potential for undue influence should be used. These might include posting notices to invite volunteers from the entire group concerned, for example, in the waiting room of the medical clinic, or for the entire school rather than one particular class. The notices, in these cases, would ask the interested individual to contact the research team for further information. At that point, the PI and/or study team can follow-up to explain the study, answer questions, and take consent, if necessary.

Guidance Note 10.1.3: Exclusion of Remuneration from Recruitment Materials

AnchorRecruitment materials that are used for the purpose of recruiting participants, such as letters, advertisements, flyers, radio or television scripts, or internet messages, should not include any information about the value of the remuneration for participation. This mitigates the possibility of inducing participants to accept potential risks for financial gain. Prospective participants may not realize that participation can only occur if they meet the conditions of the study's inclusion and exclusion criteria. The promise of remuneration in the recruitment materials may unintentionally mislead some prospective participants into thinking that they will automatically be enrolled into the study. There may be circumstances specific to the study where this general principle should not apply. In such cases, applicants should explain the rationale for needing to include remuneration information in the recruitment materials and the REB may allow an exception to the general rule.

Guidance Note 10.1.4: Allowing Sufficient Time for Prospective Participants to Consider Participation

AnchorRecruitment should be done in such a way that prospective participants have adequate time between the time of initial contact to the actual consent phase to consider whether or not they wish to participate. For example, for non-minimal risk studies, prospective participants who are attending a clinic for elective or scheduled procedures should not normally be approached and asked to consent to participate in a study at that time. They may be invited to participate in the study and if interested, given the consent form, which they can return, should they decide to participate.

For studies involving more than minimal risk, twenty four hours is often considered an appropriate amount of time to give participants to think about participating in a study. However, the time given to consent should be based on the nature of the study in question. The TCPS2 states that the time required for initial consent should "depend on such factors as the magnitude and probability of harms, the complexity of the information conveyed, and the setting where the information is given."TCPS 2 (2018), Section of Article 3.2

Guidance Note got 10.1.5: Third Party Recruitment and Snowball Sampling

AnchorIn most cases, the REB will not permit third party recruitment or snowball sampling techniques in clinical research. Research participants should not be asked to identify potential participants as this may put both the participant and the people they contact into a variety of uncomfortable situations, e.g. undue influence over the participant to recruit from the research team or over the recruited from the participant recruiter.

In some situations, the REB may allow this type of recruitment when justified, e.g. research on a genetic condition that may run in a family. In these cases, the researcher should outline the process to reduce potential undue influence on the person being recruited. For example, the third party may distribute an introductory letter describing the study with details on how to contact the researcher, if they are interested in participating. Details of how third-party recruitment will be accomplished and copies of any letters sent to either the third party or to the participant via the third party must be provided for review by the REB.

Guidance Note 10.1.6: Initial Contact by Telephone

AnchorThe UBC clinical REBs generally do not permit that researchers make initial contact with potential research participants by telephone unless they have previously consented to be contacted about participating in research. A letter of initial contact should be mailed to the potential participants that outlines when the telephone call will occur, by whom, and give participants the option to opt-out of receiving the telephone call, e.g. list a number they can call or email address they can write to request that they not be contacted further. See Guidance Note 10.3.1 below for specific inclusions for the letter of initial contact.

See Guidance Note 14.6.1 for information regarding initial contact by telephone in emergency situations.

Guidance Note10.2: Examples of Recruitment Methods


Guidance Note 10.2.1: Study Nurses or Research Coordinators

AnchorA study nurse or research co-ordinator who co-ordinates studies out of a specialized medical clinic can make direct initial contact with a prospective participant who is attending the clinic for patient care or for research purposes. This avoids any potential undue influence from a physician/researcher and eliminates the need to extract contact information from medical charts. The study nurse/co-ordinator must identify him/herself and explain his/her relationship to the clinic/medical department at the time of contact with the prospective participant.

Guidance Note 10.2.2: Initial Contact by a Personal Care Physician who is also a Principal Investigator

AnchorProspective participants under a Principal Investigator's care may also be contacted by mail, using an REB approved initial contact letter. The letter can be followed up by a telephone call after a reasonable length of time. The letter should stipulate who will make the follow-up phone call and when this will occur. While the PI should be the signatory on the letter of initial contact, it is preferable to have a study nurse/co-ordinator make the follow up telephone contact, for the reasons outlined in Guidance Note 10.1.2. See Guidance Note 10.3.1 below for a detailed list of what should be included in the letter of contact.

Important Note: Principal Investigator's should become involved in the consent process whenever explanations are required or questions are asked which the person making the initial contact is unable to provide.

Guidance Note 10.2.3: Recruitment from School Populations

AnchorBritish Columbia's school districts vary in their requirements for conducting research involving teachers, staff or students. School Boards can be contacted concerning their specific policies. It is the responsibility of the investigator to know and comply with the local school board policy. Documentation of school approval should be provided to the REB. If required by local policy, the REB may issue their approval of the research, conditional upon school board approval, so that the Researcher may supply the UBC REB approval to the school board for its consideration.

Guidance Note 10.2.4: Contact with Prospective Participants through Sponsors' Call Centres

AnchorSometimes prospective participants provide their contact information to sponsors' call centres. This information is then sent to a local study centre for follow up. This practice is permissible; however, researchers must describe the procedure to the REB in the REB application, including providing the REB with the script used by the call centre to receive calls, and all screening scripts. Investigators contacting potential participants under these circumstances must provide the prospective participants with an explanation of how they obtained their contact information. The REB must also be provided with written information pertaining to the sponsors subsequent use and disposition of all personal information obtained by the sponsor in this manner.

Guidance Note 10.3: Recruitment Materials

AnchorAll recruitment material used must be approved by the REB in the form it will be used in before recruitment begins, e.g. a newspaper ad and a poster should be submitted separately even if the text is only slightly different. Recruitment materials should give potential participants a basic understanding of the research, what would be expected of them (including time commitment), and their potential eligibility for the study. Include directions for the potential participant to contact the research team, if they believe they are interested in the study. All recruitment material should be labeled with a version date. Do not include any payment or remuneration value for participation on the recruitment material; however, you may mention an honorarium, gift, or small token of appreciation etc. will be given.  See Guidance Note 10.1.3 above.

Guidance Note 10.3.1: Letter of Initial Contact

AnchorFor VCH contact used:

Note that for this method of recruitment, the Letter of Initial Contact must come from the VCH Department as opposed to the Principal Investigator, as per VCH policy. Please revise the Letter of Initial Contact accordingly.

If VCH is providing the patient’s contact information, the VCHRI Letter of Initial Contact Template must be used Refer to the VCH template found here.  

and Client Contact Agreement.  If the researcher or department has already received permission to contact, from the patient, for research purposes, through another program, this template does not need to be used however, please adhere to UBC CREB Guidelines: Refer to the UBC Clinical Guidance Notes, http://ethics.research.ubc.ca/ore/ubc-clinical-research-ethics-general-guidance-notes#art10pt3pt1


A letter of initial contact should be used when initially contacting any person whose contact information was obtained from medical records, databases, or registries as per Guidance Note #11.Note that although the PI should sign the letter, the REBs prefer that any follow-up phone call be done by a research nurse or coordinator. The letter of Initial contact should include the following:

  1. The full study title and name of the PI.
  2. Why the potential participant is being invited to take part in the study;
  3. How the research team obtained their contact information. This should include the relationship of the researcher to the department/clinic/ unit where the information was housed (if applicable);
  4. Brief overview of the study;
  5. If a telephone call will occur, a statement of when it will occur and by who should be included. The participants should be given an option to opt-out of being further contacted and a process for opting out should be described;
  6. The letter should be signed by the PI.


Guidance Note 11: Recruitment B - Use of Contact information obtained from Medical Records, Databases, and Registries
Guidance Note 11.1: Identifying and contacting Prospective Participants from Primary Health Care Provider Records

AnchorIn some situations, the prospective participant's primary care (i.e. family doctor) physician (or other primary health care provider) holds the participant's personal contact information. In these situations, permission to release the contact information must be obtained from the participant by the primary care physician before the researcher can use the information for recruitment purposes. The primary care physician must either verbally ask the prospective participants' permission to release their names to the Investigator, or distribute an introductory letter describing the study to the prospective participants, with details on how to contact the Investigator if they are interested in participating. Private practice physicians fall under the provisions of the British Columbia Personal Information Act (PIPA). PIPA section 21 regulates the disclosure by physicians of personal information for research or statistical purposes.

Guidance Note 11.2: Identification and Initial Contact of Prospective Participants from Personal Data Obtained from Public Bodies

AnchorThe BC Freedom of Information and Protection of Privacy Act (FOIPPA) applies to public sector institutions referred to in the Act as "public bodies". These include some health care (e.g. hospitals and health authorities), public (e.g. government Ministries, WCB), and educational (e.g. School boards, universities) bodies. Special rules apply to Health Ministry databases and to designated health information banks under Part 2, Division 1, Sections 3 and 4 of the E-Health (Personal Health Information Access and Protection of Privacy) Act.

Section 35 of FIOPPA limits the disclosure of personal information collected by such bodies to third party researchers such that this information cannot be released by the public body for contact purposes, unless the research purpose, the use for contact and the manner of contact are approved by the Privacy Commissioner [Section 35(2)].  This limitation does not apply to research conducted or sponsored by the public body, itself (see Article 11.5 below).

Where the disclosure of contact information under section 35 of FOIPPA is sought by a researcher for recruitment, the privacy officer or, as applicable, the custodian of the relevant database or registry should be consulted to explore the availability of options for recruitment or, if appropriate, for obtaining the Commissioner's approval for disclosure for contact purposes. Even though researchers may have access rights to the records or electronic registries of a public body for clinical or other purposes not related to the research, it is not appropriate for researchers to use such access to identify or obtain contact information about prospective research subjects without proper authority and approvals under FOIPPA.

Researchers should be aware that the REB must also review and approve the plan for initial contact and that it is within the REB's discretion to determine that such contact is not ethically acceptable notwithstanding the Privacy Commissioner's approval. [TCPS2 Article 5.6]

Guidance Note 11.3: Identification and Initial Contact of Prospective Participants from Information held by Ministry databases and by designated health information banks

AnchorPart 2, Division 3, Section14 of the E-Health Act limits the disclosure of personal information held by a Ministry database or by a designated health information bank. This information cannot be released by the bank or database for the purpose of contacting named individuals unless the request for disclosure has been approved by the Data Stewardship Committee created under the Act, and provided that the research purpose, the use for contact and the manner of contact are approved by the Privacy Commissioner (Part 2, Division 3, Section 14.2.1(c)).

Guidance Note 11.4: Information held by disease specific registries (that are not Ministry databases or designated health information banks)

AnchorParticipants who have previously consented to be included in a registry for research purposes including consented to be contacted for future research studies, must first be contacted by mail using the contact information included in the registry. The contact letter must be approved by the REB and must explain to the prospective participant how their contact information was obtained, in addition to explaining the reason why they are being contacted. See Guidance Notes 10.3.1, for specific inclusions for the letter of initial contact.

Guidance Note 11.5: Prospective Participants who are Patients of a Hospital Department / Unit or Specialized Medical Clinic

AnchorIdeally, prospective participants in clinical studies are approached for the purpose of recruitment into a research study by someone who is within their circle of clinical care (see "Circle of Care: Sharing of Information for Health Care Purposes" for further discussion).

Investigators who are not acting as health care providers for prospective participants but who are attached to a hospital department/clinical/medical unit that offers clinical care and conducts research on the patient populations of the specific unit, may be able to obtain prospective participant names from the patient lists of their hospital's medical units in order to determine eligibility for contact provided that the practice is agreed upon by the head of the unit, and the participating physicians. In such circumstances, with REB approval, prospective participants may be contacted in writing with an explanation of how their personal contact information was obtained, and a description of the Investigator's relationship to the medical unit, department or clinic. See Guidance Notes 10.3.1 for specific inclusions for the letter of initial contact.

If the investigator is not directly affiliated with the hospital department/clinical/medical unit then the inclusion/exclusion criteria should be sent to the manager of the patient database or privacy officer for the department with a request that the REB approved letter of initial contact be sent out to prospective participants so that if a patient is interested they can contact the site.

Alternatively, and only with REB approval, clinic staff may approach patients directly to advise them that a study is being conducted and to enquire if the patient would like to find out more information concerning it.  If so, patients may be referred to study staff.

Investigators should be aware that the REB will make the determination concerning the most appropriate method for initial participant contact and approved methods will depend upon the context of the study.  In most instances however, an initial contact letter offering the participant the opportunity to contact study staff if they are interested in a study is preferred as it provides prospective participants the option to contact the investigator or not and avoids the possibility of unsolicited personal approaches. 


Guidance Note 12: Risks and Benefits
Guidance Note 12.1: Risks and Benefits Related to Research

AnchorThe TCPS 2 (2018) states that "the analysis, balance, and distribution of risks and potential benefits are critical to the ethics of research involving humans. The principle of Concern for Welfare imposes an ethical obligation to design, assess and conduct research in a way that protects participants from any unnecessary or avoidable risks. In their review, the REB should be concerned with an assessment that the potential research outcomes and potential benefits merit the risks." TCPS 2 (2018) Chapter 2, Balancing Risk and Potential Benefit

UBC's REBs are responsible for determining whether the research presents an ethically acceptable balance of risks and potential benefits. The decision to participate in approved research, however, is that of the potential participant, based upon his or her own appreciation of whether it serves their interests or welfare to do so. With this in mind, the general description of the research and the research risks and benefits should be disclosed in such a way as to avoid therapeutic misconception. It should be made abundantly clear that the primary purpose of the study is for research and not to produce therapeutic benefits for participants. Participants must clearly understand how a clinical trial design could potentially interfere with the healthcare options that are available to them in order to make an informed decision about participating. See TCPS 2 (2018) Chapter 11, Section A, Therapeutic Misconception

Guidance Note 12.2: Required Information

AnchorInformation on risks in the application and the consent form must be consistent with the information provided in the protocol and the Investigator's Brochure/Product Monograph if applicable. If risk information/data is provided from another source, the source of the data should be identified in the application.

  • Minimize Harms: Include an explanation of any strategies put in place to minimize and/or manage the harms for participants and others (e.g. reporting side effects, rescue medication, early withdrawal from the study)
  • Unknown Interactions With Other Drugs: Disclose whether the research necessitates that certain medication or treatments not be administered during the study so that potential participants may evaluate this in the context of their current health.
  • Wash-Out Periods/ Requirements for Stopping Medication: The consent form must explain the symptom/signs that participants could experience from being taken off any medication, and the potential impact on the participants health.
  • Risks to Pregnant Women and Others: Potential harms to individuals other than the participant must be noted (e.g. unborn children, sexual partners, family members). The risk of any harms to pregnant women, to women who could become pregnant during the course of the research, or to men in relation to the reproductive capacity need to be disclosed in the consent form.

Specific instructions concerning the prevention of pregnancy must be included in the consent form as follows:

  • Specific measures to take to prevent pregnancy (note: Acceptable measures will vary depending upon the Research Ethics Board)
  • How to notify the researcher if a participant suspects that she is pregnant; and
  • What would happen if a pregnancy should occur during the research.
  • Please note the University of British Columbia’s Clinical Research Ethics Board (CREB) does not require that Pregnancy Consent forms are submitted unless such a case presents.  

    If a participant or partner of the participant becomes pregnant, then a separate consent should be submitted for REB review prior to the collection of pregnancy data.  Please notify the study sponsor.

For further information about standard disclosures around risks and discomforts, see the BC Common Clinical Informed Consent Form Template, section "What are the possible harms and discomforts?".

Guidance Note 12.3: Risks That May Require Special Counselling

AnchorNote that risks to the participants may also include social harms such as breach of confidentiality, social stigmatization, threats to reputation and psychological harm. Explain what strategies are in place to minimize and/or manage the risks for participants and other affected individuals.

It is the PI's responsibility to ensure that any harms such as psychological distress, arising from any knowledge that participants could obtain as a result of their participation in any type of research study, be eliminated if possible, and if elimination is not possible that such harms be minimized to the greatest extent possible.

In the course of research, there are tests that might have results that impact seriously on the research participant's health or have other serious implications (e.g. HIV, Hepatitis, some genetic tests, etc.) Appropriate pre- and post-test counselling services shall be made available to the participant and when appropriate, to his or her family.

Guidance Note 12.4: Genetic Testing

AnchorSome studies may provide results to participants which identify them as belonging to a high-risk group on the basis of the result (e.g. genetic status, biochemical test result). TCPS2 Article 13.2 specifies that in the case of research involving individuals, families, and groups in genetic research, the researchers must describe a plan to manage "the types of information that may be revealed through genetics research - and the implications of this information for participants and their biological relatives". TCPS2 Article 13.4 requires that "where researchers plan to share results of genetic research with participants, the research proposal should make genetic counselling available at that time, where appropriate." This will normally require making both pre- and post-testing counselling available. See Article 12.3 above.

In addition, some genetic testing may provide results to participants which identify them as belonging to a high-risk group on the basis of their genetic status. If this may be the case in the context of the specific study, the consent form must include a statement that informs participants that any knowledge gained from the research study that identifies the participants as belonging to a high-risk group, may reduce the ability of the participant to obtain health and/or life insurance.

Article 12.5: The Risk of Not Being Able to Receive Study Treatment Following Termination of the Study

AnchorDue to the possibility of not being able to continue on treatment after a study is completed, the following wording should be included in the consent form. See the BC Common Clinical Informed Consent Form Template, section "After the study is finished":

You may not be able to receive the study treatment after your participation in the study is completed. There are several possible reasons for this, some of which include:

  • The treatment may not turn out to be effective or safe.
  • The treatment may not be approved for use in Canada.
  • Your caregiver may not feel it is the best option for you.
  • You may decide it is too expensive and insurance coverage may not be available.
  • The treatment, even if approved in Canada, may not be available free of charge.

If the participant received a device, explain if they will keep the device or not (i.e., “The device that was implanted for this study will not be removed, but it will continue to be monitored as part of standard or usual care.”)

Guidancen Note 12.6: Quantification of Risks to Research Participants

AnchorUBC REBs require numeric (usually percentage) quantification of risks wherever possible. Quantify the foreseeable risks of harms (side effects) or inconveniences (discomfort to incapacity) to the participant associated with each procedure (including radiation risks from X-rays, therapy, test, interview or other aspect of the study). For specific guidance on X-Rays, please see Guidance Note #17. Quantification should include information about the seriousness and consequences of the different types of adverse events that have been observed, as well as the probability of these events occurring. Quantification of these harms should emphasize the incremental risk with the experimental intervention as compared to placebo or no treatment, wherever possible.

The following information (and any other relevant information) should be included in the consent where applicable:

Explain the risk that the participant’s condition may worsen.

The CIOMS standard frequencies for Risks are outlined as follows:

Very common (10% or greater)

Common (1% - 10%)

Uncommon (0.1% - 1%)

Rare (0.01% - 0.1%)

Very rare (less than 0.01%)

Frequency not known (cannot be estimated from the available data)

  • In cases where risks from human research is not readily available (for example, Phase I studies), please provide details of any relevant risks shown in previous studies conducted on animals.
  • Disclose all known risks and discomforts associated with study procedures, including social and psychological risks/discomforts, risks to others, reproductive risks, genetic risks, risks that require counselling (describe whether counselling will be made available), and risks related to testing for reportable diseases, and risks related to use of placebo or associated with drug washout periods.
  • Indicate whether the harms of the study drug may be severe, disabling, irreversible, or may cause death.
  • Indicate whether the risks are fully known and whether there may be unexpected harms/side effects, including unexpected effects of novel drug combinations or because the study drug is in an early stage of development.  Provide previous study results if known.
  • Clarify the risks to women should they become pregnant as well as any risks to potential fathers (see recommended wording below);
  • Instruct participants that they should immediately inform their study doctor of any side effects they experience, if applicable;
  • Instruct prospective participants to discuss the known side effects with their study doctor prior to their decision to participate in the study;
  • Clarify that participants assigned to the placebo group may experience worsening of their condition since they will not have their condition treated.
  • List in bold text any medications, supplements, or foods that should not be taken while on the study.
  • Disclose any potential loss of opportunity to receive standard care or the related known benefits from standard care.
  • For studies that involve questionnaires or surveys, include that there may be potential risks of  feeling anxiety / sadness etc. and that the participant does not have to answer any questions that make them feel uncomfortable. 

Unanticipated side effects: The consent form must include an explanation that unanticipated side effects, including severe or irreversible ones, could occur if a novel combination of drugs is being tested, even if the individual drugs are not expected to have these side effects.

Guidance Note 12.7: Benefits

AnchorResearch benefits can be direct, e.g. a health condition improves, or indirect, e.g. the research benefits a group in which the participant belongs. As stated in the TCPS 2 (2018), "researchers should be sensitive to the expectations and opinions of participants regarding potential benefits of the research." (TCPS 2 (2018), Chapter 4, Fairness and Equity in Research Participation ) The consent form and the application should specify the benefits to the prospective participants. If there are no direct benefits to the participants from participating in the research, this must be stated explicitly. If any specific therapeutic benefits cannot be assured, but may be hoped for by the participant, state explicitly that the participant may or may not benefit from participation in the study. For sample wordings around the benefits of participating in a research project, see the BC Common Clinical Informed Consent Form Template, section "What are the potential benefits of participating?".


Guidance Note 13: Informed Consent: General Principles and Application

Free and informed consent lies at the heart of ethical research involving human participants. The Tri-Council Policy Statement 2 (TCPS 2 (2018)) defines consent to mean "free, informed and ongoing." (TCPS 2 (2018) Chapter 3: The Consent Process) Individuals are generally presumed to have the capacity to make free and informed decisions about participating in research when properly informed of the purpose of the research and its risks and benefits. As a general rule, informed consent should be sought from all research participants (see Guidance Note #13 and Guidance Note #14 for exceptions to this standard).

The REB must be provided with a clear description of who will approach a potential participant, who will obtain consent, and what is the relationship between the person obtaining consent and the participant. All consent documents and methods must be approved by the REB before a potential participant is consented to take part in the research project.


Guidance Note 13.1: General Principles of Informed Consent
Guidance Note 13.1.1: Consent Shall be Given Voluntarily

AnchorTCPS 2 (2018), Article 3.1

Consent should be given voluntarily, free of undue influence or coercion. Undue influence may arise when a person in a position of authority or a person in a dependency relationship is involved in the consent process, e.g. employers and employees, physician and patient, or professor and student. Coercion is a more extreme form of undue influence and can result in harm or perceived harm, if a potential participant fails to participate see Guidance Note #10 on recruitment to ensure these situations are avoided. In order to maintain voluntariness, participants are free to withdraw from a research project at any time and without providing a reason. They do not need to express their desire to withdraw in writing. If there are any circumstances where a participant's data cannot be withdrawn, these circumstances must be clearly disclosed in the consent form.

Guidance Note 13.1.2: Consent Shall be Informed

AnchorTCPS 2 (2018), Article 3.2

Researchers are responsible to ensure that a potential participant or authorized third party is provided with full disclosure of the necessary information needed to make an informed decision. A list of required elements for informed consent can be found in Article 3.2 of the TCPS 2 (2018).

Guidance Note 13.1.3: Consent Shall be an Ongoing Process

AnchorTCPS 2 (2018), Article 3.3, ICH-GCP 4.8.2

Consent is an ongoing process. It is the duty of the researcher to ensure that participants are provided with all information relevant to their ongoing consent to participate in the research. Researchers must respect any display of dissent on part of a research participant. Any changes to the consent form or other documents given to participants must be approved by the Research Ethics Board prior to circulation to participants. See Guidance Note 13.5.1 below for further information about ongoing consent and new research risks.

Guidacne Note 13.1.4: Material Incidental Findings in Individual Research Participants

AnchorTCPS 2 (2018), Article 3.4 Within the limits of consent provided by the participant, researchers shall disclose to the participant any material incidental findings discovered in the course of research.

An “incidental finding” is a discovery about research participants or prospective participants that is made in the course of research, but is outside the objectives of the research study. Incidental findings are considered to be material incidental findings if they are reasonably determined to have significant welfare implications for the participant or prospective participant. Material incidental findings may appear at any stage of the research. For example, material incidental findings can be discovered while screening for eligibility to participate in a study, while collecting baseline information, during study procedure, or during follow-up evaluations.

Determination of materiality

To determine whether an incidental finding is material, expertise relevant to the finding is required. If researchers do not have such expertise, and are unsure of how to interpret the findings or are uncertain whether findings are material, they should seek expertise relevant to the finding and/or refer to professional practices and standards.

Management of foreseeable and non-foreseeable material incidental findings

Incidental findings can arise in any type of research. In some areas of research, such as genetic or genomic research and research that includes imaging, material incidental findings can reasonably be foreseeable in the specific participant population for the study. Where material incidental findings are foreseeable, researchers shall inform participants, as part of the initial consent process, of the likelihood of discovering material incidental findings, and where applicable, should provide information on their strategy to disclose such findings to participants. In addition, researchers should develop a management plan for review by the REB. For genetic research, researchers are required to develop a plan for managing information that may be revealed through their research, and submit the plan for REB review (Article 13.2).

In other areas of research, material incidental findings may not be reasonably foreseeable, but can be discovered unexpectedly in the course of the research. Upon discovery of an incidental finding, the researcher shall determine whether the finding is material, and report the discovery to the REB in accordance with guidance in Article 6.15. The researcher should describe the process used to determine the materiality of the finding(s), and present a plan for disclosing such findings to the participants.

Regardless of whether the material incidental findings were foreseeable, REBs should assess the researcher’s plan to disclose material incidental findings to participants. If there is uncertainty as to whether a research project requires such a plan, researchers and REBs can make this determination on a case-by-case basis. The final decision on the need for a plan rests with the REB.

Consent and departures from consent

Upon discovery of a material incidental finding, the principle of Concern for Welfare places an obligation on researchers to share it with the relevant participants. To respect the participants’ autonomy, the communication of the findings determined to be material can only be done when participants or their authorized third parties have consented to receiving them initially or as part of the ongoing consent process. See Articles 3.1, 3.2 and 3.3 for the consent process and Article 13.3 for human genetic research).

Where the researchers have undertaken, in the course of the consent process, not to disclose material incidental findings, and researchers discover an unforeseeable material incidental finding that can be addressed with a potentially significantly beneficial intervention, researchers should consult their REBs to determine whether there is a sufficient ethical basis to disclose the finding to the participant, and if so, how to disclose it.

There may be limitations to the consent to receiving material incidental findings. For example, in the case of children, authorized third parties, who, by law, must always exercise their authority in the best interest of the child, must receive any findings for the child that are actionable immediately or during childhood.

Researchers should exercise care and sensitivity in determining who discloses material incidental findings that may have a negative impact on the welfare of participants, and how that disclosure is made. Researchers should assist participants in understanding the material incidental finding(s). Researchers’ assistance may include suggesting that participants consider seeking additional advice from people they trust, such as family members, friends, experts or professionals. When necessary, researchers should direct participants to a qualified professional to discuss the possible implications of material incidental findings for their welfare.

In some cases, incidental findings may trigger legal reporting obligations. Researchers should be aware of these obligations and, as part of the initial consent process, should inform participants of the limits to confidentiality (Article 5.1).

Exceptions to the obligation to disclose

Researchers may also request an exception to their obligation to disclose material incidental findings, based on the impracticability or impossibility of disclosing such findings to the participant. “Impracticable” refers to undue hardship or onerousness that jeopardizes the conduct of the research; it does not mean mere inconvenience. Disclosure may be impossible or impracticable when participants or their authorized party may be deceased or difficult to track due to insufficient identifiers, cost, or time elapsed. The onus is on the researcher to justify to the REB the need for the exception.

Guidance Note 13.1.5: Consent Shall Precede Collection of, or Access to, Research Data

Anchor(TCPS 2 (2018), Article 3.5)

Research shall begin only after the participants, or their authorized their parties, have provided their consent. Exceptions to this are discussed in Guidance Note #13 and Guidance Note #14.

Guidance Note 13.2: Consent Documentation

AnchorAs stated in the TCPS 2 (2018), Article 3.12, evidence of consent shall be contained either in a signed consent form or in documentation by the researcher of another appropriate means of consent. In most circumstances, the UBC clinical REBs require that informed consent be documented by the use of a written consent form approved by the REB and signed and personally dated by the participant or the participant's legally authorized representative. The investigator should allow the participant or the legally authorized representative adequate opportunity to read the consent document before it is signed and dated. A signed and dated copy of the document must be given to the person signing the form. See UBC REB SOP 701 for further discussion of the documentation of informed consent.

The written informed consent document should be in plain language understandable to the participants of the study, e.g. at a grade 7 level. See the BC Common Clinical Informed Consent Form Template for reference.

Where consent is not documented in a signed consent form, researchers may use a range of consent procedures, including oral consent, study notes and other strategies, for documenting the consent process. Consent may also be demonstrated solely by the actions of the participant (e.g., through the return of a completed questionnaire). Where there are valid reasons for not recording consent in writing, the procedures used to seek consent must be documented and approved by the REB. TCPS 2 (2018), Article 3.12

Exception: For research that is funded or supported by the US federal government, a REB may only waive the requirement for a signed consent form for some or all participants in accordance with applicable US Federal regulations, see UBC REB SOP 701, 4.8.2


Guidance Note 13.2.1: Translated Consent Documents

AnchorTranslated consent forms must be submitted to the REB accompanied by an English version of the same. The researcher should ask for the translated version to be independently reviewed for accuracy. A copy of the translated consent document must be submitted to the REB for approval along with a statement signed by the interpreter confirming that the translation is accurate, stating the name and version date of the document they translated and their qualifications. This may be submitted as an amendment after the REB has approved the English version. The participant will sign the translated consent.

Note that a translated consent document does not replace the requirement for a translator/interpreter to be present during the consent process and throughout study. When using a translator for communication between the research team and participants, the research team should use someone who has appropriate command of the language to ensure accurate communication.  See Article 5.2 of the TCPS 2 (2018) for ways to mitigate potential loss of confidentiality when using a translator.

If a translator assisting in the consent process is using the English consent form, the consent form must include a signature, printed name of the translator, and the name of the language it was translated into, on the signature page of the consent form.

Guidance Note 13.2.2: Use of Facsimile, Mail or E-mail to Document Informed Consent

AnchorThe REB may approve a process that allows the informed consent document to be delivered by mail, facsimile or e-mail to the potential participant or the potential participant's legally authorized representative and to conduct the consent interview by telephone when the participant or the legally authorized representative can read the consent document as it is discussed. All other applicable conditions for documentation of informed consent must also be met when using this procedure.

Guidance Note 13.2.3: Oral Presentation of Informed Consent Information

AnchorOral presentation of informed consent information may be used in limited circumstances such as when the proposed participant is illiterate or blind. In such cases, special care needs to be taken that the participant and/or the legally authorized representative are provided with all the elements of consent orally. The REB also must review and approve a written summary of the information that will be presented orally. This summary must be signed by a witness and the person consenting. The signature of the witness is intended to attest to the fact, and to state, that what is included in the summary was actually said to the participant or legally authorized representative. It does not attest to the comprehension of the participant.

Guidance Note 13.3: Directions for Obtaining Consent

AnchorThe person obtaining consent must be sufficiently familiar with the study, the disease being treated (if applicable), and the process of informed consent. This will usually be the investigator or a designated research assistant. Consent in most cases should be obtained in a face to face discussion with the potential participant and legal representative, if applicable.

For guidance on electronic consenting please see here

Guidance Note 13.4: Documentation of study participation in Medical Record

AnchorWhen medically relevant to the safety of participants, the investigator should independently document the obtaining of informed consent in the medical record, noting the date, the participant's full understanding of the risks and benefits of enrollment, the voluntary nature of participation, and if required, a copy the consent form. If participation in a clinical research study or if it is the intention or a likely consequence of the research that test results, which might affect treatment decisions or have important implications (e.g. HIV tests, genetic tests), will become part of the participants' health record, this must be disclosed in the consent form.

For studies which are using electronic medical records (EMRs) and will have the consent form as part of the EMR (e.g. Cerner), please include the following required wording.  Please note this wording should also be amended and used accordingly for studies where the hard copy consent form will be placed in the patient’s medical record:

“Because this is a treatment study, your signed consent form will be included in your electronic medical record, and your healthcare team will be alerted that you are on a study. This is to ensure your healthcare team has a little information about the study so that they can treat you safely according to the study protocol.”

Guidance Note 13.5: Standard Consent Methods and Additional Information

AnchorThe following is standard UBC guidance around specific research situations regarding informed consent. Standard informed consent disclosures can be found in the BC Common Clinical Informed Consent Form Template. If you are unable to find appropriate guidance for your research, contact the applicable Research Ethics Board administration.

Guidance Note 13.5.1: New Information about Risk

AnchorWhen previously unknown/undisclosed risks of research become available, researchers are required to inform all relevant participants and their legal representatives (if appropriate) of this information within an appropriate timeframe. The timeframe depends on the nature of the study and the consequences of the risk. This may involve the following:

  1. Informing the participants(s) verbally of additional risks or changes in procedures and ensuring that the communication of this information is documented in the study notes;
  2. Informing the participants in writing of the additional risks via an addendum or amendment to the consent form. Note that in situations where the new information may affect the participants' willingness to remain in a study, the participant should be informed of these changes in writing, e.g. revised informed consent form or addendum; (ICH-GCP 4.8.2.) and
  3. Informing the participants who have completed their study treatment if the newly identified risks could still affect them (e.g. irreversible or delayed adverse effects).

Any new or revised information given orally or in writing, including changes to the consent form (or consent addenda), information letters, or telephone scripts must be submitted to the REB for approval before use.

Guidance Note 13.5.2: Timing of Consent

AnchorThe UBC REBs consider a consent given by a participant to be effective upon the signing the consent form or the giving of oral consent. The REBs do not recognize consent given after the fact, unless this was pre-approved by the REB for specific types of research, e.g. research in emergency situations, see Article 14.2 and UBC REB SOP 502, Article 3.1. As per Article 10.1.4, for studies involving more than minimal risk, twenty four hours is often considered an appropriate amount of time to give participants to think about participating in a study. However, the time to consent should be based on the nature of the study and should be justified in the application.

Guidance Note 13.5.3: Consent for Participation in a Sub study

AnchorThe consent form should outline any plans for a sub study and either indicate that a new consent form will be provided or provide check boxes so that potential participant can decide whether they also want to participate in the sub study. If participation in the sub study is not optional, this should be clearly disclosed in the consent form and a justification provided to the REB.

Guidance Note 13.5.4: Consent for Participation in an Extension Study

AnchorIf a study protocol includes a provision/plan for an extension study, the initial study consent form should mention that the participant might be offered an opportunity to participate in another longer-term study after this initial study is finished.

An entirely separate informed consent process must be administered at the time of enrollment into the extension study, using a specific consent form dedicated to the extension study. In most cases, extension study must be submitted as a new application referencing the initial study so that the REB can review the results of the main study, e.g. safety data, before approval.

Guidance Note 13.5.5: Consent in Tissue Banking and Data Registries

AnchorThere are specific consent requirements for studies that involve the creation of or an addition to a tissue bank or data registry. See Guidance Note #16 for information about the consent process in these situations. Please also see the CREB Guidance for Research Involving Human Biological Materials. Note that for studies that involve tissue banking and/or requests to enter participants' information in a data registry, this should be optional unless it is being collected for purposes directly related and integral to the study at hand. A specific tissue banking or data registry consent form should be prepared and participants consented separately from the main study. If the study poses no direct benefit to participants, researchers may require consent to both the study and the tissue bank or registry as a condition of participating. This is ethically acceptable because the study is not using the incentive of direct benefit to induce participants to participate in an unrelated procedure or activity. Thus, there is no prospect of undue influence in recruiting participants.

Guidance Note 13.5.6: Consent and Studies that use Photography, Video recording, and Audiotaping

AnchorIf there are any plans to use photography (including digital photographs), video or audio recordings in the research, who will have access to the recordings and the methods used to protect the participant's identity must be described in the consent form. The eventual fate of the records must also be disclosed (i.e. where and for how long they will be stored, if there are any plans for secondary uses of the recordings, and whether they will be destroyed). If there are plans to use these materials for any other purpose than the research outlined in the consent form (e.g. for teaching purposes) and participants could be identified, a separate consent form is required.

Guidance Note 13.5.7: Human Genetic Research

AnchorStudies involving genetics that have the potential to identify disease predisposition must disclose this in the consent form and give participants the opportunity to choose what type of information they wish to know about themselves. Genetic counseling should also be made available and discussed in the consent form. (TCPS2, Article 13.3.)

Guidance Note 13.6: Standard and Mandatory Consent Disclosures

AnchorUBC's REBs mandate standard required disclosures with respect to the following topics. Refer to the BC Common Clinical Informed Consent Form Template for detailed information and standard wordings.

Guidance Note 13.6.1: Confidentiality

AnchorSee section 16 ("How will my taking part in this study be kept confidential?") of the BC Common Clinical Informed Consent Form Template and Article 16.2 on Privacy and Confidentiality for information on confidentiality and specific consent form disclosures. Any alterations to the required wordings must be justified to the REB.

Guidance Note 13.6.2: Disclosure of Personal Identifiers on Data sent Off-site

AnchorIf there is planned disclosure of personal identifiers (e.g. names, date of birth, or initials) outside the local study site, or if such personal identifiers are used on study documents or any research-related information or are part of the unique identifier, this must be justified to the REB. See section 16 of the BC Common Clinical Informed Consent Form Template for further information.

Guidance Note 13.6.3: Data Transferred out of Canada

AnchorResearch data that is being sent outside of Canada must be approved by the REB and clearly disclosed in the consent form. See section 18 of the BC Common Clinical Informed Consent Form Template for further information on specific disclosure requirements.

Guidance Note 13.6.4: Child Abuse and other Reportable Offences


Some research may involve an increased possibility of reports of child abuse or other reportable offences. The Child, Family and Community Service Act of B.C. requires that anyone who has reason to believe that a child may be abused, neglected, or is for any other reason in need of protection, must report it to the Director or a designated social worker (Ministry of Children and Family Development). See Child, Family and Community Service Act, Article 14.  The REB may require that a sentence be included in the consent form disclosing to participants that reports or allegations of abuse must be reported to the proper authorities. See the BREB Guidance under the confidentiality section of the Consent Form Guidelines.

In situations where there may be a breach of confidentiality, the researcher may state that a participant's "information may be disclosed if required by law”.


Guidance Note 13.6.5: Reportable Diseases

AnchorUnder the BC Health Act Communicable Disease Regulation, physicians/researchers are required to report some communicable diseases to provincial health authorities (e.g. Hepatitis B or C, Human Immune Virus (HIV), West Nile Virus, etc). If there is a possibility that a participant will be tested for one of the reportable diseases, this must be disclosed to the participants in the consent form. See section  How will my taking part in this study be kept confidential? of the BC Common Clinical Informed Consent Form Template for further information on specific disclosure requirements.

Guidance Note 13.6.6: Primary Care Physician(s) and Specialist(s) Notification of Study Participation

AnchorIf notification of a participant's primary care physician or specialist is mandatory for the participation in a study, this must be disclosed in the consent form. If notification is optional, then a checkbox should be provided in the consent form. See section 16 of the BC Common Clinical Informed Consent Form Template.

Guidance Note 13.6.7: Disclosure of Race and Ethnicity


If applicable, collection of data on demographic features such as race/ethnicity, birthplace, gender, and sexual orientation must be justified in the ethics application and the reason for the collection explained to participants in the consent form. They must also be told that providing this information is voluntary. See section 16 of the BC Common Clinical Informed Consent Form Template.

Guidance Note 13.6.8: Disclosure of Legal Rights

AnchorThe consent form should not contain language that causes or appears to cause the participant to waive their legal rights. (ICH-GCP 4.8.4) The participant should also not bear the cost of illness or injury arising from their participation in a research study. The Consent form should outline how potential injury or illness obtained as a result of participation in research will be covered. See section 17 ("What happens if something goes wrong?") of the BC Common Clinical Informed Consent Form Template for further information and required disclosures.

Guidance Note 13.6.9: Receiving the Study Drug after Study Completion

AnchorFor all studies that involve a study treatment that may not be accessible to participants after the study is finished for a variety of reasons, e.g. too expensive, not approved, not effective, this must be disclosed in the consent form. See section 21 ("After the study is finished") of the BC Common Clinical Informed Consent Form Template.

Guidance Note 13.7: Informed Consent Form Administrative Requirements

AnchorUBC's REBs have administrative requirements for research consent forms in relation to the following topics. Refer to the BC Common Clinical Informed Consent Form Template for detailed information and standard wordings.

Guidance Note 13.7.1: Participants' Rights

AnchorIf research participants have concerns or complaints about their rights or experiences as research participants, they should contact the Research Participant Complaint Line in the UBC Office of Research Ethics by email at RSIL@ors.ubc.ca or phone at 604-822-8598 (Toll Free: 1-877-822-8598). This contact information should be outlined in the consent form making it clear that this line is not intended to answer questions about a participants' study treatment or to provide emergency medical care for a research related injury.

Guidance Note 13.7.2 Required Signatures on the Consent Form

AnchorThe REB requires that the participant and the person obtaining consent sign and date the consent form. Except in special circumstances, e.g. where oral consent is necessary, the REBs do not require a witness signature on consent forms. Note that the Principal Investigator is responsible for ensuring the consent process is followed whether they conduct the process or not. For further information about required signatures, see section 22 ("Signatures") of the BC Common Clinical Informed Consent Form Template.

Guidance Note 13.7.3 Referencing the REB in the Consent Form

AnchorThe UBC REBs accept (but do not require) references in consent forms to the research project having been reviewed by the Research Ethics Board (REB). Avoid using language that indicates that it is the role of REBs to ensure the well-being or safety of participants or that the study received favourable review.

Guidance Note 13.7.4 Use of Check Boxes in Consent Forms

AnchorThe use of "Yes/No" check boxes for consent is not allowed. Lack of a signature on a consent form is taken as evidence of dissent, and no participant shall be required to declare in writing that they do not consent to participate in a research project.

Exception to the above: Where a single consent form contains multiple optional sub-components, (e.g. tissue banking for genetic research) where participants can choose which ones they wish to participate in, the optional SUB-COMPONENTS (but not the main question of consent to participate in the main project) may employ "Yes/No" indicators to signify willingness to participate.

Lack of indication of "Yes" (or equivalent) shall be taken as evidence of DISSENT and no requirement to check "No" (or equivalent) is allowed.

The REB may require that separate consent forms fully describing a sub-component(s) of a project be developed in some cases.

Guidance Note 13.7.5 Listing the Co-Investigators on the Consent Form


AnchorThe REBs prefers that all co-investigators, their institutional affiliation (i.e. use the local site in a multi-site trial) and appropriate titles be listed after the PI on the consent form. Where it is not practical to do so, the REBs accepts that only the PI (including their telephone number) be listed on the consent form. BCCA has separate requirements regarding listing co-investigators on the consent form. See the BC Common Clinical Informed Consent Form Template, section "Principal Investigator, co-investigator, sponsor, emergency contact" for further information.


Guidance Note 14: Departures from General Principles of Consent

This guidance note describes circumstances when some of the general principles discussed in GN #12 can be waived, altered, or temporarily suspended.

Guidance Note 14.1: Waiving Consent in Minimal Risk Research

AnchorThe TCPS2, Article 3.7A, states the REB may approve research without requiring that the researcher obtain the participant's consent where the REB is satisfied, and documents, that all of the following apply:

  1. the research involves no more than minimal risk to the participants;
  2. the lack of the participant's consent is unlikely to adversely affect the welfare of the participant;
  3. it is impossible or impracticable to carry out the research and to answer the research question properly, given the research design, if the prior consent of the participant is required;
  4. whenever possible and appropriate, after participation, or at a later time during the study, participants will be debriefed and provided with additional pertinent information in accordance with the TCPS 2, Articles 3.2 and 3.4, at which point they will have the opportunity to refuse consent in accordance with the TCPS 2, Article 3.1; and
  5. the research does not involve a therapeutic intervention, or other clinical or diagnostic interventions. (TCPS2, Article 3.7.)

It is the responsibility of the researcher to demonstrate that a particular research project fits into the above criteria. This should be done by listing each of the above criteria and an explanation as to why the research fits into it underneath. This may entered into the RISe application Box 6.7A.

Guidance Note 14.2: Waiver of Consent in Individual Medical Emergency Situations

AnchorThere are situations where an individual who requires urgent medical care is unable to provide consent for research due to loss of consciousness or capacity and the delay to seek authorized third party consent could seriously compromise that individual's health. In these cases and subject to all applicable legal and regulatory requirements, research involving medical emergencies may be conducted only if it addresses the emergency needs of the individuals involved, and then only in accordance with criteria established in advance of such research by the REB. NOTE: This section does not apply to publically declared emergencies, e.g. SARS. See TCPS2, Article 3.8 to read more about research conducted during publically declared emergencies. (TCPS2, Article 3.8 (paragraph just above))

As stated in the TCPS2, Article 3.8, the REB may allow research that involves medical emergencies to be carried out without the consent of participants, or of their authorized third party, if all of the following apply:

  1. a serious threat to the prospective participant requires immediate intervention;
  2. either no standard efficacious care exists or the research offers a realistic possibility of direct benefit to the participant in comparison with standard care;
  3. either the risk is not greater than that involved in standard efficacious care, or it is clearly justified by the prospect for direct benefits to the participant;
  4. the prospective participant is unconscious or lacks capacity to understand the risks, methods and purposes of the research project;
  5. third party authorization cannot be secured in sufficient time, despite diligent and documented efforts to do so; and
  6. no relevant prior directive by the participant is known to exist.

When a previously incapacitated participant regains capacity, or when an authorized third party is found, consent shall be sought promptly for continuation in the project, and for subsequent examinations or tests related to the research project. (Ibid, 3.8.)

Research in emergency medicine must be reviewed by the REB, be restricted to the emergency needs of the participants, and be conducted under criteria designated by the REB. The above outlines the minimal conditions necessary for the REB to authorize a research without free and informed consent.

Guidance Note 14.3: Waiver of Consent in Individual Medical Emergency Situations

AnchorAs stated in Chapter 5, Section D of the TCPS2, secondary use refers to the use in research of information originally collected for a purpose other than the current research purpose. Common examples are social science or health survey datasets that are collected for specific research or statistical purposes, but then re-used to answer other research questions. Information initially collected for program evaluation may be useful for subsequent research. Other examples include health care records, school records, biological specimens, vital statistics registries or unemployment records, all of which are originally created or collected for therapeutic, educational or administrative purposes, but which may be sought later for use in research. (TCPS, Chapter 5, Section D)

Researchers who have not obtained consent from participants for secondary use of identifiable information shall only use such information for these purposes if the REB is satisfied that the following TCPS2 (Article 5.5) requirements are met:

  1. identifiable information is essential to the research;
  2. the use of identifiable information without the participants' consent is unlikely to adversely affect the welfare of individuals to whom the information relates;
  3. the researchers will take appropriate measures to protect the privacy of individuals, and to safeguard the identifiable information;
  4. the researchers will comply with any known preferences previously expressed by individuals about any use of their information;
  5. it is impossible or impracticable to seek consent from individuals to whom the information relates; and
  6. the researchers have obtained any other necessary permission for secondary use of information for research purposes.

The researcher must satisfy all of the above conditions for the REB to approve the research without requiring consent from the individuals to whom the information relates. (TCPS2 5.5) Researchers must ensure that they specifically address each of these requirements in the context of their application for waiver of consent by responding to each article individually.

For the purpose of these Guidance Notes, identifiable information is information that may reasonably be expected to identify an individual, alone or in combination with other available information. All research that involves the secondary use of identifiable information either must seek informed consent or request a waiver of informed consent using the above criteria. All research where the investigators only have access to de-identified information, but a link either does exist or did exist, must still submit for REB review; however, a request for waiver of consent is not required. Only secondary use of anonymous information, where information was collected anonymously, e.g. a link never existed, may qualify to be exempt from REB review as per Article 4.3.

Guidance Note 14.4: Secondary use of human biological Materials for Research Purposes

AnchorSecondary use of biological material refers to the use in research of any material that was originally collected for a purpose outside of the current research purpose. This involves biospecimens that are already collected and stored such as materials that were collected for an earlier project, biospecimen from an institute's Pathology Department or biospecimen from a certified biobank. Informed consent is required for the secondary use of identifiable human biological material unless the researcher can satisfy the REB that the criteria outlined in TCPS 2 Article 12.3 are met. Note that secondary use of biological materials left over after diagnostic tests is only authorized when there is no further current or future clinical need for those materials and the Pathology Department has released the specimens for research use. See the TCPS 2 (2018) Chapter 12, Section C for further discussion of consent and the secondary use of biological information.

Please note that prospective collection of samples does not fall under the category of secondary use and researchers must satisfy the research consenting requirements by either (1) creating a consent form for the prospective collection or (2) applying for a waiver addressing TCPS2 article 12.3. Please note that consenting prospective participants is required unless the REB has determined that a waiver of consent can be justified.  

Scenario:  A patient undergoing surgery as a part of clinical care has a biospecimen removed.  These samples are then discarded as per clinical SOPs.  Rather than having samples discarded, researchers would like to collect these samples for research.  This researcher is required to submit an ethics application and consent participants for the use of their biospecimens for research.

Guidance Note 14.5: Consent for contact for additional information after use of waived consent

AnchorIn situations where a waiver of consent was granted by the REB or when a researcher wants to re-contact a former participant for further information without their explicit consent for re-contact, the researcher must provide the REB with a plan for making contact with the participant. This plan must be approved by the REB before contact is made. The plan should include the following:

  1. Demonstrate that the potential benefit of the follow-up contact clearly outweighs the risks to individuals;
  2. Explain who will contact and invite the individuals to participate;
  3. Describe the nature of the relationship of the above persons to the individuals.

The researchers must ensure that their method of contact complies with applicable privacy laws. The REBs prefer that the contact be made by the custodian of the original data set rather than the researcher. (TCPS 5.6.) The consent form should also explicitly state the process by which the waiver was authorized and indicate a contact who the potential participant can call or email, if they have further questions or concerns.

Guidance Note 14.6: Types of Research where a Consent Waiver or Alteration may be Appropriate

AnchorThe following section provides examples where a waiver or alteration to the consent process may be appropriate.

Guidance Note 14.6.1: Initial Contact by Telephone in Medical Emergencies

AnchorResearch involving individual medical emergencies should follow TCPS2 Article 3.8, see Article 14.2 of this Guidance Note. However, if time allows, third party consent should be attempted before proceeding with a waiver of consent in an emergency situation. In these situations, the REBs allow a researcher to contact a legal representative or next of kin by telephone to give consent on behalf of the participant. This process should only be used when face-to-face consent with a legal representative or next of kin is not possible. The researcher should clearly describe for the REB the consent process that will be used ensuring to include the following: who will make initial contact and discuss the study over the phone, what consent form will be read over the phone, clarification that the participant will be given some time to decide, e.g. 30 minutes. A witness and the person reading the consent form should sign the original consent form. The time and date it was read, and the name of the participant must also be entered into the original consent form. The research team should obtain written consent when possible from the legal representative (e.g., by fax or e-mailing a scanned and signed form) and full informed consent from the participant when they are able.

Guidance Note 14.6.2: Research Involving Deception

AnchorAlthough clinical research involving deception is rare, clinical research that does involve deception requires justification of the deception by meeting all the requirements of TCPS2 Article 3.7 (See Article 14.1 of this Guidance Note). A simple test for possible deception is to ask yourself: "Is there any information in the procedures section of the ethics application that I would not be willing to tell the participant in the study prior to their participation?" If the answer to this is yes, then deception is involved. This deception information, and the rationale behind its exclusion from the initial consent form, must be provided to the participants in a debriefing after participation. Participants must also be able to indicate their consent or their refusal to include their information in the study at the end of the project, following the debriefing process.

Guidance Note 14.6.3: Studies involving Questionnaires Only

AnchorWhere a study involves the completion of a de-identified or anonymous questionnaire the return of a completed questionnaire may be taken as evidence of consent. The researcher should prepare an introductory letter/consent form and it must state the following or the like: If you wish to participate in this research study and are comfortable with the procedures described in this letter/form, please complete the attached questionnaire and email/return it back to us.

Guidance Note 14.6.4: Chart Reviews

AnchorClinical chart data or medical records used in research is considered secondary use of data. Informed consent or a clear argument for waiver of consent is required for collecting prospective and retrospective clinical data. See Article 5.5 of the TCPS2 and 14.3 of this Guidance Note for further information.

Chart reviews that involve the use of retrospective data only, generally fulfill the TCPS2, Article 5.5, criteria for waiver of consent for the use of secondary use of data in research. However, the request for waiver should still be outlined on page 6 of the REB application. Note that for the purposes of UBC REB review, retrospective data collection can only include data that is dated before the date of ethics approval. Any data that is collected on an ongoing basis is considered prospective data collection and consent is generally required.


Guidance Note 15: Capacity to Consent and Research Involving Participants with Diminished, Diminishing, or Developing Capacity

The following sections deal with research involving participants with diminished, diminishing, or developing capacity to consent. It discusses determining capacity, situations where research is appropriate in populations with developing, diminished or diminishing capacity, including research with children, and lastly provides a framework for how to obtain consent and assent in these situations.

Guidance Note 15.1: Determining Capacity to Consent

AnchorCapacity is the ability of prospective or actual participants to understand relevant information presented (e.g. purpose of the research, foreseeable risks, and potential benefits), and to appreciate the potential consequences of any decision they make based upon this information. (TCPS 2, Chapter 3, C.) The TCPS2 states that a participant may have developing or diminished capacity, i.e. a minor or person with a cognitive impairment, but still be able to decide whether to participate in certain types of research (ibid). If a potential research participant has the capacity to consent, consent must be sought from them before research with them commences. If a person does not have the capacity to consent, they should still be involved in the consent process where possible and appropriate and given the opportunity to assent. If a person who lacks the capacity to consent declines to participate in research, his or her dissent must be respected and the person may not be included in the research, see Article 15.5 for further discussion on assent and dissent.

Capacity to consent to research is not a static determination; it may vary over time, and upon the complexity and circumstances of the decision being made. It is the responsibility of the Principal Investigator (PI) to determine and monitor participants' capacity to consent and to describe this to the REB in the context of the proposed study.

Guidance Note 15.1.1 Capacity in those with cognitive impairments and diminishing or fluctuating capacity

AnchorResearchers should describe the population with whom they are doing research, and how they will assess capacity. This may include cognitive tests designed for determining a persons' capacity, e.g. the mini mental. The application should outline how the PI and study team will continue to monitor a participant's consent to participate when their capacity is diminishing or fluctuating. This should include details of obtaining consent from a third party, in the event that the participant can no longer consent to participate in the research. See Article 15.5.1 below for further information. If a participant regains capacity, the researcher must obtain their consent to continue to participate in the research. The REB may require that Investigators re-consent participants after taking into account the study's anticipated length and the condition of the individuals to be included (e.g., participants with progressive neurological disorders). Researchers are encouraged to contact a UBC REB for advice on specific situations involving people with fluctuating or diminishing capacity to consent.

Guidance Note 15.1.2 Capacity in those under the age of majority

AnchorThe legal age of majority in BC is 19. However, depending on the nature of the research, a participant may have the capacity to consent well before the age of majority. BC law does not specifically prevent a person under the age of majority from consenting to participate in research. The common law has two well accepted doctrines that are applicable to the consent of minors. The first is the "emancipated minor" doctrine, and the second is the "mature minor" doctrine.

The emancipated minor doctrine, which is commonly applied by UBC's REBs, provides that persons under the age of majority who are "emancipated" in the sense of living on their own, earning their own income, etc. are generally capable of consent, because they are "emancipated from parental control and guidance."

The mature minor doctrine is a common law rule that takes the varying abilities of young people into account, and recognizes that some minors are able to make decisions for themselves. Generally, at common law, if a minor has reached a level of intellectual and emotional maturity such that he or she is capable of understanding and appreciating the nature and consequences of a particular treatment / decision, together with its alternatives they can be considered capable of consenting. Put another way, if it can be determined that a minor in fact understands the proposed interventions, can properly weigh the risks and benefits of various procedures, understands other courses of action and their implications, and it is not prohibited from consenting by legislation, a minor may give a legally valid consent.

There is some debate concerning whether the mature minor doctrine applies in instances where treatment is not beneficial or therapeutic, but increasingly the "rights of minors" to decide are being recognized, except in the most extreme cases, e.g. life and death situations.

The ability to consent to research is not based upon on a participants age or whether they have reached the age of majority. In accordance with the TCPS2 and in keeping with Article 15.1 above, capacity to consent to research is premised upon an individual's ability to understand the nature of the research and the consequences of participation in the research project. The Panel on Research Ethics (PRE) stresses that no two research studies or research participants are the same. Therefore, the researcher plays an important role in determining whether a particular research participant is capable of consenting on their own behalf or whether an authorized third party should be used. (Panel on Research Ethics) Within the same research project, there may be some minors who are capable of consenting and others who are not. As per Article 15.1 above, the researcher should describe to the REB how the study team will determine capacity to consent to the research for those proposed participants who are under the age of majority. The PRE advises that factors to consider in making the decision to seek consent from children should include the following: the level of risk the research may pose to participants, provincial legislation and other applicable legal and regulatory requirements related to legal age of consent, and the characteristics of the intended research participants. (Panel on Research Ethics)

Guidance Note 15.2: Conditions for Research with People lacking in Capacity to Consent

AnchorResearch involving individuals who lack the capacity, either permanently or temporarily, to decide for themselves whether to participate, must meet at a minimum the following conditions in order to be considered for REB approval:

  1. the researcher involves participants who lack the capacity to consent on their own behalf to the greatest extent possible in the decision-making process;
  2. the researcher seeks and maintains consent from authorized third parties in accordance with the best interests of the persons concerned;
  3. the authorized third party is not the researcher or any other member of the research team;
  4. the researcher demonstrates that the research is being carried out for the participant's direct benefit, or for the benefit of other persons in the same category. If the research does not have the potential for direct benefit to the participant but only for the benefit of the other persons in the same category, the researcher shall demonstrate that the research will expose the participant to only a minimal risk and minimal burden, and demonstrate how the participant's welfare will be protected throughout the participation in research; and
  5. when authorization for participation was granted by an authorized third party, and a participant acquires or regains capacity during the course of the research, the researcher shall promptly seek the participant's consent as a condition of continuing participation. (TCPS2 3.9)
Guidance Note 15.3: Who can be an Authorized Third Party and Obtaining Third Party Consent

AnchorAn authorized third party is any person with the necessary legal authority to make decisions on behalf of a prospective participant who lacks the capacity to consent to participate, or to continue to participate, in a particular research project. This person should not be part of the research team and should adequately know the person whom they are representing to take into account any previously expressed opinions regarding participating in research. Family members and friends may also provide information to the authorized third party about the interests and previous wishes of prospective participants.

When an authorized third party is being used to consent on behalf of a person with diminished or developing capacity, the BC Common Clinical Informed Consent Form Template should be used to develop the consent form, and it should be amended to be clear that the third party is consenting on behalf of the research participant. The following paragraph or the like is required to appear in the consent form in cases where the participant assents to participate in the research:

The parent(s)/guardian(s)/authorized third party and the investigator are satisfied that the information contained in this consent form was explained to the child/potential participant to the extent that he/she is able to understand it, that all questions have been answered, and that the child/potential participant assents to participating in the research.

Inclusion of this statement in the consent form places the obligation on the authorized third party, who is providing consent, and on the investigator to ensure that the participant/child assents and understands the information in the consent form to the extent that he/she is able.

A separate assent document with wording aimed at the level of the potential participant may also be appropriate and is not precluded by the addition of this statement to the consent form. See Article 15.6 below.

Guidance Note 15.4: Research Directives

AnchorWhere individuals have signed a research directive indicating their preferences about future participation in research in the event that they lose capacity or upon death, researchers and authorized third parties should be guided by these directives during the consent process. (TCPS2 3.11) If a person who has signed a research directive retains sufficient capacity to assent or dissent to the research, and they decline to participate, their dissent must be respected.

Guidance Note 15.5: Assent

AnchorWhere an authorized third party has consented on behalf of an individual who lacks legal capacity, but that individual has some ability to understand the significance of the research, the researcher should determine the wishes of that individual with respect to participation. If this person "assents" to the research, they are agreeing with or concurring with the consent of their authorized third party. While the individuals assent would not be sufficient to permit them to participate in the absence of consent by an authorized third party, their expression of dissent or signs suggesting they do not wish to participate must be respected and precludes their participation. Those who may be capable of assent or dissent include:

  1. those whose capacity is in the process of development, such as children whose capacity for judgment and self-direction is maturing;
  2. those who once were capable of making an autonomous decision regarding consent but whose capacity is diminishing or fluctuating; and
  3. those whose capacity remains only partially developed, such as those living with permanent cognitive impairment. (TCPS2 3.10)

UBC's REBs do not consider lack of assent or dissent to be equivalent to refusal to participate. Caution and special care should, however, be taken in these circumstances. The research must fit all of the criteria outlined in Article 15.2 and the third party decision maker must take into account any previous preferences regarding participation in research expressed by the potential research participant. The researcher should document the lack of assent or dissent in the research record. The researcher must respect any expressions or displays of dissent during participation in the research.

Guidance Note 15.5.1 Obtaining Assent from a Research Participant with Third Party Consent

AnchorWhen a third party is used for consent of a person who lacks capacity, the researcher still must determine the willingness of the prospective participant to take part in the research. This is generally done through a face-to-face interview with the prospective participant and the principal investigator. This interview must convey the main information contained in the consent form using concepts and terms that are developmentally and cognitively appropriate. If the prospective participant is able to read, an assent form should be prepared in a language that is appropriate to the participant. Note: For studies starting after Sept. 2012, the CREB no longer accepts an assent statement attached at the end of a consent form, but rather all participants who are capable of assenting should sign a separate form labeled as such. This may be similar to the main consent form, if the person is capable of reading the language in the main consent, but should be labeled as an assent form. The following elements should be included in the assent form:

  1. a description of the purpose, procedures and the potential risks, discomforts, and hoped for benefits of participation, including possible benefits to others. The CREB recognizes that it will often be appropriate to give this information summarily and with less precision than is normally found in a consent form. Nevertheless, the information should not be so scant that a participant is surprised by aspects or consequences of their participation;
  2. a statement of the amount of time that participation in the study will take;
  3. a statement that the participant's confidentiality will be respected, e.g. that the participant's involvement will be kept private;
  4. a statement that participation is voluntary, that the participant may refuse to participate at any time without giving reasons, e.g. no one connected with the study will be angry if a decision to leave the study is made after giving assent, and that all other health care will remain available.
  5. statements that prospective participant has had the opportunity to ask questions, is encouraged to discuss his or her participation with relatives or friends, and that all questions have been answered.
  6. a statement that questions are encourages and may be asked at any time.

The assent form should be as brief as reasonably possible, e.g. for children under 12 it should not exceed 2 pages. Merely technical information, such as the name of the sponsor, disclosure of an investigator's financial interest, advice that legal rights are not limited by participating etc. can typically be omitted. The participant must receive a copy of the assent form and have had adequate time to review it and to discuss it with relatives or friends and the principal investigator (or delegate) prior to assenting.

Guidance Note 15.5.2 Preparing Assent Forms for Younger Children (7-13)

AnchorIn addition to the above, when preparing assent forms for children it is especially important to convey information that is sensitive to their perspectives on the procedures, risks, discomforts, and inconveniences that they will encounter. For example, it may be appropriate to explain to children what they will experience simply by being in a hospital (for example, that they will be in a room with other children, that they will have to spend most of their time in a hospital bed and will not be able to get up and walk around without immediate supervision or that they will be able to walk around unsupervised, that their parents will not be able to be with them all the time, that they will spend a certain number of nights away from home, that they will be looked after by nurses and doctors, etc). Also, it will typically be appropriate to describe how the research procedures will change how they feel or look (for example, that a medication will make them dizzy or itchy, or that they will be connected by tubes to a machine, or that they will have a scar and what it will look like). For an example of a template suitable for children click here.

Guidance Note 15.5.3 Assent in Children Younger than 7

AnchorChildren who are under 7 years old and who are capable of assent will not normally be capable of reviewing an assent form. Investigators should follow the procedures as per Article 15.6. Any dissent from the child must be respected.

Guidance Note 15.6 Informing and Obtaining agreement of Parents of Consenting Children

AnchorWhen a child under the age of majority is deemed to have the capacity to consent, they can consent for themselves, unless there is a legislative prohibition, which restricts their ability to consent in particular circumstances. In BC, there is no legislation that has been interpreted as restricting children with capacity to consent, from consenting to research.

However, in some situations parental agreement may be appropriate or necessary. For example, the research may be taking place in institutions that have specific requirements about research involving children or it may be sponsored by a company that also has requirements in this regard. In these cases, a parental consent form as well as a child's consent form may be necessary. For example, the Vancouver School Board requires parental consent for all research that is taking place in its schools. In these situations, researchers should seek consent from the capable child and consent from the parents, using separate forms. Both parties must consent before the research can take place. If the child consents and the parent does not, the child cannot participate in the research despite being fully able to consent. This is not UBC's REBs policy, rather it is due to the school board's requirements. In order to be able to conduct research within the Vancouver School Board, their requirements must be complied with. The same is true for sponsored studies where adult / parental consent is a requirement of the Sponsor.

In the same way that there are clearly examples of cases where it would be inappropriate or possibly even harmful to inform the parents of children capable of consenting to certain research about their child's participation, (e.g. some kinds of research concerning abortion or other sensitive subjects) there may be other instances where it would be appropriate or courteous to obtain the agreement of a capable child's parents, or at least to ensure that they are informed that the research is taking place. Researchers should consider the specific nature and context of their research, and determine what they deem to be appropriate. UBC's REBs will make the final determination as to what they deem to be necessary in the context of the research that they are reviewing.


Guidance Note 16: Research Databases and Registries

This guidance note applies to research databases and registries, including databases for general research purposes and databases for multiple research uses over an extended period of time. It regulates the creation, maintenance, and use of repositories that collect and store information about humans specifically for use in subsequent research. The information may include personally identifying information, clinical files, clinical test results, x-rays, MRIs, information about race, age, or place of origin, etc., that is collected retrospectively or prospectively. This guidance note does not apply to databases and registries that are created specifically for clinical/health purposes.

Guidance Note 16.1: Informing Potential Participants and the REB

AnchorThe information described below must be conveyed in the consent form and in the Application for Ethical Review in ways that will be meaningful to prospective participants and the REB:

  1. The type(s) of data to be collected and the period over which they will be collected (which in this guideline includes identifying data, such as names, initials, telephone numbers, addresses, personal health numbers, etc.);
  2. The purpose(s) for which the data will be used;
  3. The limits on the use, disclosure, and retention of data, including descriptions of access by other researchers, any planned linkages to other databases, and types of studies to be conducted;
  4. The entity or person(s) who have custodianship of the data and the address of the database or registry;
  5. The measures in place for protecting the security of the data and participant confidentiality, including a description of the de-identification or coding of the data and of what steps will be taken to ensure the security of the database (e.g., password protections, data encryption, secure rooms, etc.);
  6. A description of who will have access to identifying data, the nature of that information, and who will have a key linking coded data to identifiable participants;
  7. A description of any identifying data, or linked or coded data, or data that is fully de-linked and anonymised, that will be sent outside Canada, and to whom it will be sent (e.g. individuals, organizations, regulatory agencies), and where it will be stored (provide local address and country);
  8. The risks associated with possible disclosure of identifying data, including non-physical risks associated with accidental disclosure of genetic or other information that could result in discrimination by employers, insurance providers, or others;
  9. A description of any commercial uses for which the data may be used, including any disclaimers about participant remuneration;
  10. Any foreseeable circumstances where disclosure of identifying data is required by law (e.g., for reportable diseases [Article 13.6.5] or child abuse [Article 13.6.4]);
  11. Any anticipated secondary uses of identifying data from the research, and whether participant consent will subsequently be sought for such uses;
  12. Any anticipated linkage of the data gathered in research with other data about participants (whether those data are contained in public or personal records);
  13. Any modes of observation (e.g., photographs or videos) or access to information (e.g., sound recordings) in the research that allow identification of particular participants (see Article 13.5.6);
  14. Any access participants have to the data and rights to amend or withdraw data or to withdraw permission to obtain data, including a description of who to contact for these purposes (requests to withdraw permission to obtain data must not be required in writing);
  15. A description of how long the data will be retained and whether identifying data will be destroyed or returned to the participant.


Guidance Note 16.2 Further Requirements for Information Disclosure to the REB

AnchorIn addition to the information described above, researchers must satisfy the REB of the following in the Application for Ethical Review:

  1. A full description is provided of the data stewardship processes for overseeing the management and use of the data, including the main rules governing use of the database, the process by which access requests will be reviewed, and the organization to whom the researcher is accountable for the proper management of the data;
  2. Data is being obtained from research participants only insofar as it is necessary for the research.
  3. Specific and appropriate justification has been provided for collection and use of identifying data, including any use of identifying data on case report forms or other database or registry documents (e.g., names, initials, telephone numbers, addresses, personal health numbers, etc.).
  4. De-identification of data will occur as quickly as possible.
  5. Access to identifying data and to the key linking identifying data to de-identified data has been limited to the minimum number of properly trained personnel that is reasonable in the circumstances.
  6. Database personnel have appropriate training in, and comply with, security and privacy safeguards.
  7. Identifying data will not be retained for longer than is necessary to fulfill research purposes (at which time they should be destroyed or returned to the participant- see A. xvi above). [See AGN 8.6 and Food and Drug Act Regulations: Division 5 Section C.05.012 (4) regarding retention of records.]

Changes to 16.1 or 16.2 above require REB approval through the normal study amendment process.

The CREB may require additional information in the consent form or in the Application for Ethical Review.

Guidance Note 16.3: Definitions

AnchorIdentifying/Identifiable Data: information that can directly or indirectly identify an individual. This includes information: a) that contains an individual's personally identifying information (e.g., name, initials, address, telephone number, date of birth, personal health numbers, full face photographic images, etc.), or b) for which there is a reasonable basis to believe the information could be used to identify an individual.

De-identified Data: information where an individual's identifying information has been removed, and where there is no reasonable basis to believe that the information could be used to identify an individual. De-identified data may nevertheless be coded (e.g. via a confidential master list created by the researcher) so that the information can be linked to the individual and his/her clinical or other records. See AGN 8.4 for further directions on coding that is consistent with de-identification of data.

Anonymous/anonymised data: this refers to information that cannot be linked back to an individual either directly or indirectly (i.e., the information contains no identifying information, no master list or coding remains anywhere linking a participant to the information, and there is no reasonable basis to believe that the information could be used to identify a participant).


Guidance Note 17: Special Categories of Research: Research Involving Radiation Exposure (Note: this Guidance Note is in Draft Form, May, 2012)
Guidance Note 17.1: Research Involving Radiation Exposure

AnchorUBC's REBs make case-by-case judgments about the merits of research in light of the risks posed. As radiation exposure escalates, expectations of risk minimization and prospect of direct benefit will proportionally escalate. This guidance focuses on improving communication with research participants about radiation risk.

When using radiation or radioactive materials in human participants, the study should be designed to use minimum radiation doses following prevailing medical radiation exposure guidance, and those that are as low as reasonably achievable (the "ALARA" principle).

Radiation exposure includes the dose from all radionuclide procedures and all diagnostic radiology procedures related to the research study, together with doses from other research studies in which the participant may be participating or has participated in previously. Repeated use of the same volunteers for different projects involving radiation exposure is discouraged. Similarly, it may be inappropriate to involve participants with substantial prior radiation exposure. UBC's REBs understand that the risk of exposure to radiation is cumulative over a lifetime.

While radiation is categorized by the FDA as a known carcinogen, considerations pertaining to informing participants of radiation risks need to be tailored to the particular circumstances of the study population. For example, communication of risk to cancer patients who may be participating in studies that involve exposure to radiation would be quite different than communication of risk to adults without cancer. Similarly, risks to adults over 50 are somewhat lower, and risks to children are higher, due to their heightened sensitivity.

Guidance Note 17.2: Assessment/ Categorization of Radiation Risk

AnchorUBC's REBs base their understanding of the risks of radiation on the European Commission document noted below.

"Radiation protection 99, Guidance on Medical Exposures in Medical and Biomedical Research, 1998" https://ec.europa.eu/energy/sites/ener/files/documents/099_en.pdf

The European Guidance describes the following primary categories of radiation risk:

Category 1: Effective doses less than 0.1 mSv (adults)

This category involves a risk (total detriment from the radiation exposure for normal participants of less than one in a million.

Category 2a: Effective dose range 0.1 - 1 mSv (adults)

This category involves risks of the order of one in a hundred thousand.

Category 2b: Effective dose range 1 - 10 mSv (adults)

This category involves risks to the irradiated individual of the order of one in ten thousand.

Category 3: Effective doses greater than >10 mSv (adults)

Here the risks to the irradiated individual are estimated at greater than one in a thousand.

The risks referenced in the categories, are "lifetime risk of death [from cancer] due to hematologic or solid organ malignancy".

The categories noted apply to healthy adults (those without cancer) under 50 years of age. The dose figures may be increased by a factor of 5 - 10 for individuals over 50. In the event that approval is being sought for research on children, the corresponding dose figures should be reduced by a factor of 2 or 3.

Guidance Note 17.3: Informing / Disclosing risks of radiation to research participants

AnchorUBC's REBs (with the exception of the BC Cancer REB) recommend that the following principles be adhered to in all study-related communications about the risk of radiation exposure:

  1. 1. State the effective dose (or dose range) in mSv.
    The conversion factor between the mSv and Radiation Equivalent Man (REM) units is 10mSv=1 rem.
  2. Describe the exposure in terms of common life events, such as:
    Chest radiograph 0.02 mSv (The Royal College of Radiologists. Making the best use of clinical radiology services: referral guidelines. London: The Royal College of Radiologists, 2007, page 17, Table 2.)
    Natural Background radiation 2.4 mSv / year (Mettler FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, Lipoti JA, Mahesh M, McCrohan JL, Stabin MG, Thomadsen BR, Yoshizumi TT. Radiologic and nuclear medicine studies in the United States and worldwide: Frequency, radiation dose and comparison with other radiation sources - 1950 - 2007.)
    A guide to the exposure associated with various other procedures is available at http://www.radiologyinfo.org/en/safety/index.cfm?pg=sfty_xray#3
  3. Describe the risk in absolute based on the categories and age adjustments in section 20.1.2. and disclose that the risk being referred to is "your lifetime risk of dying from cancer".
    For example, the additional risk of fatal cancer from a single 20 mSv exposure in a person <50 years old is 1 in 1000 or 0.1%.
  4. Mention the time horizon over which the risk occurs. For example, "If it were to occur, it could take many years or decades for you to develop cancer related to this study."
    The latent period for cancer induction is estimated to be 6 to 10 years for blood borne cancers (leukemia, lymphoma) and 10 to 25 years for solid organ cancers.
  5. Disclose to research participants that the risk from all sources of radiation is cumulative over a lifetime.

Investigators requiring assistance in estimating the levels of risk or the practical equivalents should speak with the Radiation Protection Officer of their institution. Researchers conducting studies with participants who have cancer should consult with the BC Cancer REB concerning the need to include any specific information pertaining to radiation risks in their proposed studies.

Guidance Note 17.4: Positron-Emitting Radiopharmaceuticals (PERs)

AnchorResearchers conducting studies utilizing positron-emitting radiopharmaceuticals should consult with the 2006 interim compliance policy and guidance documents found at:



Health Canada:


Health Canada:

"Factors considered in the assessment of risks involved in the use of positron emitting radiopharmaceuticals in basic research involving humans"



International Commission on Radiological Protection)[§361.1(b)(3)(iv)].


Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine


The European Commission document "Radiation protection 99, Guidance on Medical Exposures in Medical and Biomedical Research, 1998" https://ec.europa.eu/energy/sites/ener/files/documents/099_en.pdf

Radiology Info: A guide to the exposure associated with various other procedures is available at http://www.radiologyinfo.org/en/safety/index.cfm?pg=sfty_xray#3

Part B: RISe Application Guidance Notes (AGNs)

AnchorAppendix: Acronyms and Glossary 


AGN: Application Guidance Note

BCC: British Columbia Cancer 

C&W: Children's & Women's

CREB: Clinical Research Ethics Board

GN: Guidance Note

PHC: Providence Health Care

PI: Principal Investigator

QA/QI: Quality Assurance/Quality Improvement

REB: Research Ethics Board

TCPS2: Tri-Council Policy Statement (2nd version)

U.S. DHHS: United States Department of Health and Human Services

VCHRI: Vancouver Coastal Health Research Institute


For a complete guide to ethics definitions please refer to the Glossary of the TCPS2. The most common definitions have been added below.

Anonymized information- The information is irrevocably stripped of direct identifiers, a code is not kept to allow future re-linkage, and risk of re-identification of individuals from remaining indirect identifiers is low or very low.

Anonymous information- The information never had identifiers associated with it (e.g. anonymous surveys) and risk of identification of individuals is low or very low.

Biobank- An organized collection of searchable human biological materials stored for one or more specific or future unspecified research purposes. It may also include associated information about individuals from whom biological materials were collected.

Coded information- – direct identifiers are removed from the information and replaced with a code. Depending on access to the code, it may be possible to re-identify specific participants (e.g., the principal investigator retains a list that links the participants’ code names with their actual names so data can be re-linked if necessary).

De-identified Data: information where an individual's identifying information has been removed, and where there is no reasonable basis to believe that the information could be used to identify an individual. De-identified data may nevertheless be coded (e.g. via a confidential master list created by the researcher) so that the information can be linked to the individual and his/her clinical or other records. See AGN 8.4 for further directions on coding that is consistent with de-identification of data.

Directly identifying information- the information identifies a specific individual through direct identifiers (e.g., name, social insurance number, personal health number).

Human biological materials: *Please note that UBC uses the term biospecimens in the RISe application and guidance notes. Tissues, organs, blood, plasma, skin, serum, DNA, RNA, proteins, cells, hair, nail clippings, urine, saliva, and other body fluids. The term also includes materials related to human reproduction, including embryos, fetuses, fetal tissues and human reproductive materials.

Identifiable information - Information that may reasonably be expected to identify an individual, alone or in combination with other available information. Also referred to as "personal information."

Impracticable: Incapable of being put into practice due to a degree of hardship or onerousness that jeopardizes the conduct of the research; it does not mean mere inconvenience.

Indirectly identifying information- The information can reasonably be expected to identify an individual through a combination of indirect identifiers (e.g., date of birth, place of residence or unique personal characteristic).

Prospective Data: Data collected on an ongoing basis (i.e. chart information is taken from patients who are seen after the date of ethics approval)

Retrospective Data: Data collected from charts dated on or before the date of ethics approval

Secondary use of data: The use in research of information or human biological materials originally collected for a purpose other than the current research purpose.

Vulnerability: A diminished ability to fully safeguard one's own interests in the context of a specific research project. This may be caused by limited decision-making capacity or limited access to social goods, such as rights, opportunities and power. Individuals or groups may experience vulnerability to different degrees and at different times, depending on their circumstances.  Refer to Chapter 4 of the TCPS 2 for more information.